Page last updated: 2024-11-04

flumazenil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3373
CHEMBL ID407
CHEBI ID5103
SCHEMBL ID79030
MeSH IDM0008585

Synonyms (180)

Synonym
anexate
BIDD:GT0766
AC-6846
bdbm26263
MLS001076354
ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),3,5,10,12-pentaene-5-carboxylate
chembl407 ,
[3h]ro15-1788
ro15-1788
HY-B0009
HMS3267P09
HMS3393D17
AB00572626-12
AB00572626-13
BRD-K98769987-001-01-3
smr000058450
mazicon
MLS000028850 ,
ro-151788
romazicon
flumazepil
ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
flumazenilum [latin]
c15h14fn3o3
ethyl 8-fluoro-5-methyl-5,6-dihydro-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester
ro 151788
ro-15-1788
flumazenilo [spanish]
ro 15-1788
brn 4763661
ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
lanexat
EU-0100506
flumazenil, >99% (hplc), solid
NCGC00025116-01
NCGC00015439-01
tocris-1328
lopac-f-6300
LOPAC0_000506
flumazenilum
CHEBI:5103 ,
flumazenilo
BPBIO1_001190
PDSP2_001761
BIOMOL-NT_000285
UPCMLD-DP137:001
78755-81-4
C07825
flumazenil
MLS000759529
DB01205
UPCMLD-DP137
flumazenil (jan/usp/inn)
D00697
romazicon (tn)
8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester
NCGC00025116-03
NCGC00025116-05
PDSP1_001778
NCGC00025116-04
NCGC00025116-02
NCGC00015439-03
HMS2051D17
F 6300
HMS2089B15
NCGC00015439-07
ro-1722
ro-41-8157
nsc-759193
ro-151788000
ro 15-1788/000
ethyl 8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
NCGC00015439-06
8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester
A839484
ethyl 8-fluoranyl-5-methyl-6-oxidanylidene-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
HMS3261F13
ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate
unii-40p7xk9392
flumazil
40p7xk9392 ,
nsc 759193
flumazenil [usan:usp:inn:ban]
roma
nsc759193
MLS001424108
pharmakon1600-01505701
cas-78755-81-4
dtxsid2023064 ,
dtxcid703064
tox21_110148
HMS2234F06
CCG-100968
NCGC00015439-02
NCGC00015439-05
NCGC00015439-04
NCGC00015439-08
NCGC00015439-09
flumazenil (ro 15-1788)
FT-0630863
LP00506
flumazenil [orange book]
flumazenil [inn]
flumazenil [jan]
ro-15-1788/000
flumazenil [vandf]
flumazenil [usan]
flumazenil [mart.]
flumazenil [usp-rs]
flumazenil [who-dd]
flumazenil [ep monograph]
flumazenil [mi]
flumazenil [usp monograph]
ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
CS-0629
S1332
AKOS015888159
gtpl4192
HMS3374E10
[11c]flumazenil
ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate
gtpl4367
[11c]flumazenil (pet ligand)
SCHEMBL79030
NC00218
tox21_110148_1
NCGC00015439-11
tox21_500506
NCGC00261191-01
ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylate
8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, ethyl ester
Q-201122
ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate #
ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepin-3-carboxylate
fumazenil
8-fluoro-5,6-dihydro-5-methyl-6-oxo -4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, ethyl ester
HB0915
F0958
AB00572626_15
AB00572626_14
OPERA_ID_1516
mfcd00242764
flumenazil
flumazenil, united states pharmacopeia (usp) reference standard
HMS3657K11
SR-01000075879-3
SR-01000075879-7
sr-01000075879
SR-01000075879-1
SBI-0050490.P002
SW197598-2
BCP07573
Q421920
Z1546610479
HMS3676G20
AS-13923
HMS3412G20
FYP ,
BRD-K98769987-001-12-0
SDCCGSBI-0050490.P003
HMS3884G11
NCGC00015439-22
AMY39505
F-145
ethyl 8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate.
NCGC00015439-14
flumazenil- bio-x
BF164469
flumazenil (usp-rs)
flumazenil (ep monograph)
ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
flumazenil (usan:usp:inn:ban)
v03ab25
flumazenil (usp monograph)
flumazenilum (latin)
flumazenil (mart.)
ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0,2,6]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate
EN300-123018
flumazenil, 1mg/ml in ethanol

Research Excerpts

Overview

Flumazenil is an imidazobenzodiazepine derivative that antagonizes the actions of benzodiazepines. It is a specific, reversibly bound antagonist at benzodiazine binding sites of gamma-aminobutyric acid A receptors; these sites can be imaged using positron emission tomography with 11C-flumazinil.

ExcerptReferenceRelevance
"Flumazenil is an imidazobenzodiazepine derivative that antagonizes the actions of benzodiazepines. "( Identification of degradation products in flumazenil using LC-Q-TOF/MS and NMR: Degradation pathway elucidation.
Boucetta, H; Hang, TJ; Hu, ZL; Jiang, J; Liu, JM; Lu, YT; Song, M, 2022
)
2.43
"Flumazenil is a synthetic benzodiazepine antagonist with high affinity for the central benzodiazepine recognition site."( Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017
)
2.62
"Flumazenil is a synthetic benzodiazepine antagonist with high affinity for the central benzodiazepine recognition site."( Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017
)
2.62
"Flumazenil is an antagonist of the GABA/benzodiazepines receptor complex that might play a role in the treatment of hepatic encephalopathy. "( Is flumazenil an alternative for the treatment of hepatic encephalopathy?
Barrera, F; Reyes, D, 2017
)
2.52
"Flumazenil is a specific, reversibly bound antagonist at benzodiazepine binding sites of gamma-aminobutyric acid A receptors; these sites can be imaged using positron emission tomography with 11C-flumazenil. "( GABA(A) receptor imaging with positron emission tomography in the human newborn: a unique binding pattern.
Chugani, HT; Kumar, A; Muzik, O, 2013
)
1.83
"Flumazenil acts as a benzodiazepine receptor antagonist (subunits α1, α2, α3, and α5) or partial agonist (subunits α4 and α6)."( Endogenous ligands of benzodiazepine binding site have inverse agonistic properties.
Hess, L; Malek, J; Sliva, J; Votava, M, 2013
)
1.11
"Flumazenil is an effective benzodiazepine (BZD) antagonist. "( Lack of adverse effects from flumazenil administration: an ED observational study.
Cumpston, K; Nguyen, TT; Rose, SR; Troendle, M; Wills, BK, 2015
)
2.15
"Flumazenil is an imidazobenzodiazepine that promptly reverses via competitive inhibition the hypnotic/sedative effects of benzodiazepines on gamma-aminobutyric acid receptors. "( Effect of flumazenil on bispectral index monitoring in unpremedicated patients.
Bornemann, H; Dahaba, AA; Metzler, H; Rehak, PH; Wang, G; Wu, XM, 2009
)
2.2
"Flumazenil is a benzodiazepine antagonist. "( [Seizure triggered by benzodiazepine receptor antagonist].
Pedersen, LM; Petersen, M; Søndergaard, I, 2009
)
1.8
"Flumazenil is an effective antidote but there is a risk of seizures, particularly in those who have co-ingested tricyclic antidepressants."( Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data.
Cooper, G; Dyas, J; Routledge, PA; Thompson, JP; Veiraiah, A, 2012
)
2.54
"Flumazenil is a competitive antagonist with specific action at the central benzodiazepine receptor. "( Reversal of an antihistamine-induced coma with flumazenil.
Cebrero, M; García-Frías, E; Gónzalez-Santiago, P; Lassaletta, A; Martino, R; Torrijos, C, 2004
)
2.02
"[18F]Flumazenil is a suitable radioligand for PET assessment of the BZR."( Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography.
Fedorova, OS; Gomzina, NA; Gulyás, B; Hall, H; Halldin, C; Krasikova, RN; Ryzhikov, NN; Savic, I; Seneca, N; Shchukin, E; Vassiliev, DA, 2005
)
1.04
"Flumazenil is a short-acting intravenously administered gamma-aminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. "( Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial.
Ondo, WG; Silay, YS, 2006
)
2.16
"Flumazenil is a relatively pure benzodiazepine/GABAA antagonist with limited intrinsic activity."( Effects of the benzodiazepine antagonist flumazenil in PTSD.
Bremner, JD; Charney, DS; Heninger, GR; Krystal, JH; Nagy, LM; Nicolaou, AL; Randall, PK, 1995
)
1.28
"Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines. "( Seizure after flumazenil administration in a pediatric patient.
McDuffee, AT; Tobias, JD, 1995
)
2.09
"Flumazenil is an imidazobenzodiazepine, an antagonist of central benzodiazepine (BDZ) receptors. "( Transient increase in the in vivo binding of the benzodiazepine antagonist [3H]flumazenil in deafferented visual areas of the adult mouse brain.
Frost, JJ; Madar, I; Scheffel, U, 1994
)
1.96
"Flumazenil (Romazicon) is an imidazobenzodiazepine that functions as a benzodiazepine receptor antagonist."( Effectiveness of flumazenil on return of cognitive functions after a general anesthetic.
Mok, MS; Pregler, JL; Steen, SN, 1994
)
1.35
"Flumazenil is a central antagonist of the sedative effects of benzodiazepines. "( Topics in clinical pharmacology: flumazenil, a benzodiazepine antagonist.
Longmire, AW; Seger, DL, 1993
)
2.01
"Flumazenil is an important adjunct to the diagnosis and treatment of benzodiazepine toxicity. "( Reappraisal of the "coma cocktail". Dextrose, flumazenil, naloxone, and thiamine.
Doyon, S; Roberts, JR, 1994
)
1.99
"[11C]flumazenil was found to be a more sensitive and accurate focus localiser than [18F]FDG."( Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci.
Ingvar, M; Savic, I; Stone-Elander, S, 1993
)
1.07
"Flumazenil is a competitive antagonist of benzodiazepines."( [Antagonists in anesthesia].
Calaminus, JM; Lauven, PM, 1995
)
1.01
"Flumazenil is a valid diagnostic tool for distinguishing pure benzodiazepine from mixed-drug intoxication or nondrug-induced coma. "( Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients.
Geller, E; Halpern, P; Nevo, Y; Niv, D; Rudick, V; Sorkine, P; Weinbroum, A, 1996
)
2.19
"Flumazenil is a benzodiazepine receptor antagonist. "( The effects of flumazenil in neuropsychiatric disorders.
Malizia, AL; Nutt, DJ, 1995
)
2.09
"Flumazenil is a specific benzodiazepine antagonist. "( The role of flumazenil in the critically ill.
Ferenci, P; Navapurkar, V; Park, GR, 1995
)
2.11
"Flumazenil is a selective benzodiazepine-antagonist."( Benzodiazepine receptor antagonist (flumazenil) does not affect sleep-related breathing disorders.
Köhler, D; Schönhofer, B, 1996
)
1.29
"Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. "( Flumazenil reversal of psychomotor impairment due to midazolam or diazepam for conscious sedation for upper endoscopy.
al-Kawas, FH; Benjamin, SB; Fleischer, DE; Gallagher, J; Ginsberg, G; Kankaria, A; Lewis, JH; Nguyen, CC, 1996
)
3.18
"Flumazenil appears to be a valuable adjunct for dentists who administer intravenous benzodiazepines for conscious sedation."( Flumazenil reversal of conscious sedation induced with intravenous fentanyl and diazepam.
Close, JM; Finder, RL; Moore, PA, 1995
)
2.46
"Flumazenil is a specific and competitive antagonist at the central benzodiazepine receptor, reversing all effects of benzodiazepine agonists without tranquillising or anticonvulsant actions."( A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.
Flaishon, R; Rudick, V; Sorkine, P; Szold, O; Weinbroum, AA, 1997
)
1.31
"Flumazenil is a benzodiazepine receptor antagonist that has been reported to provoke panic attacks in patients with panic disorder. "( Effect of flumazenil in lactate-sensitive patients with panic disorder.
Holsboer, F; Kellner, M; Ströhle, A; Wiedemann, K; Yassouridis, A, 1998
)
2.15
"Flumazenil is a competitive inhibitor of the benzodiazepines that is available for reversal at the end of such a procedure or when too much sedation has been achieved."( Reversal of midazolam-induced laryngospasm with flumazenil.
Davis, DP; Hamilton, RS; Webster, TH, 1998
)
1.28
"Flumazenil is a benzodiazepine receptor antagonist thought to be panicogenic in patients with panic disorder but not in control subjects. "( Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder.
Holsboer, F; Kellner, M; Ströhle, A; Wiedemann, K, 1999
)
1.99
"Flumazenil is an imidazobenzodiazepine that blocks the central effects of benzodiazepines by competitive interaction at the receptor level. "( Impact of flumazenil on recovery after outpatient endoscopy: a placebo-controlled trial.
Chang, AC; Chen, YK; Solinger, MA; Yang, DT, 1999
)
2.15
"Flumazenil is a benzodiazepine antagonist indicated for reversal of the sedative effects of benzodiazepines. "( Pharmacoeconomic evaluation of flumazenil for routine outpatient EGD.
Barnett, JL; Chaffee, BW; Elta, GH; Ryan, ML; Walter, V; Wille, RT, 2000
)
2.04
"Flumazenil is a potent antagonist of midazolam-induced sedation."( Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects.
Ebert, U; Kirch, W; Oertel, R, 2000
)
1.03
"Flumazenil-PET is a useful tool for localization of the epileptogenic zone in patients with extratemporal epilepsy caused by focal cortical dysplasia. "( Reduction of benzodiazepine receptor binding is related to the seizure onset zone in extratemporal focal cortical dysplasia.
Arnold, S; Bartenstein, P; Berthele, A; Drzezga, A; Henkel, A; Noachtar, S; Tölle, TR; Weis, S; Werhahn, KJ; Winkler, PA; Yousry, TA, 2000
)
1.75
"Flumazenil is a competitive benzodiazepine receptor antagonist, reverts the sedation effects of benzodiazepines and its effect on electroencephalographic (EEG) patterns is controversial. "( Effect of flumazenil on electroencephalographic patterns induced by midazolam.
Cotto, M; Guerrero, L; Guzmán, J; Wojna, V, 2000
)
2.15
"Flumazenil is a potent benzodiazepine antagonist that competitively blocks the central effects of benzodiazepines."( Flumazenil's reversal of myoclonic-like movements associated with midazolam in term newborns.
da Silva, O; Knoppert, DC; Zaw, W, 2001
)
2.47
"Flumazenil is a specific benzodiazepine agonist, which is reported to have a partial benzodiazepine agonist-like effect at a high dose. "( High-dose flumazenil potentiates the hypnotic activity of propofol, but not that of thiopental, in ddY mice.
Adachi, YU; Higuchi, H; Satoh, T; Watanabe, K, 2001
)
2.16
"Flumazenil is a competitive benzodiazepine antagonist that rapidly reverses the residual effects of benzodiazepines following intravenous conscious sedation. "( Reversal of central benzodiazepine effects by flumazenil after conscious sedation produced by intravenous diazepam. The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group I.
,
)
1.83
"Flumazenil is a benzodiazepine antagonist that is highly effective in reversing the central nervous system effects of benzodiazepine overdose."( Anterograde amnesia in triazolam overdose despite flumazenil treatment: a case report.
Deng, JF; Hung, DZ; Tsai, WJ, 1992
)
1.26
"Flumazenil is a new drug indicated for the reversal of the sedative effects of benzodiazepines mediated at the benzodiazepine-receptor site. "( Flumazenil and seizures: analysis of 43 cases.
Spivey, WH,
)
3.02
"Flumazenil is a specific antagonist of the central benzodiazepine receptor (CBZR). "( Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies.
Abadie, P; Albessard, F; Baron, JC; Barre, L; Debruyne, D; Moulin, M; Zarifian, E,
)
1.8
"Flumazenil is a well-known potent antagonist in benzodiazepine intoxication."( [Ethanol intoxication treated with flumazenil: a case report].
Deng, JF; Huang, FJ; Hung, DZ; Tsai, WJ, 1991
)
1.28
"Flumazenil acts as an antidote for pharmacological and toxic effects due to benzodiazepines. "( Efficacy of flumazenil in acute alcohol intoxication: double blind placebo-controlled evaluation.
Askenasi, R; Lheureux, P, 1991
)
2.1
"Flumazenil is a competitive benzodiazepine antagonist. "( Complete heart block after flumazenil.
Clarke, F; Herd, B, 1991
)
2.02
"Flumazenil is a specific benzodiazepine antagonist which is indicated when the central effects of a benzodiazepine need to be attenuated or terminated. "( Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.
Brogden, RN; Goa, KL, 1991
)
3.17
"Flumazenil seems to be a safe and efficient drug for reversing the sedative effect of midazolam, premedication after colonoscopy."( A randomised controlled trial to evaluate the effects of flumazenil after midazolam premedication in outpatients undergoing colonoscopy.
Fischer, M; Malchow, H; Mühlhofer, H; Pilot, J; Rohde, H; Saletin, M, 1991
)
1.25
"Flumazenil appears to be a promising drug for reversing midazolam conscious sedation."( Reversal of central benzodiazepine effects by intravenous flumazenil.
Clark, MS; Fryer, GE; Goldberg, JR; Jafek, BW; Lindenmuth, JE,
)
1.1
"Flumazenil is a valuable and safe differential diagnostic tool in unclear cases of multiple drug poisoning."( Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomised controlled study.
Baehrendtz, S; Gustafsson, LL; Höjer, J; Matell, G, 1990
)
2.04
"Flumazenil is an essential emergency drug when benzodiazepine-induced sedation is used."( Which agent and how to deliver it? A review of benzodiazepine sedation and its reversal in endoscopy.
McCloy, RF; Pearson, RC, 1990
)
1
"Flumazenil is a recently discovered pharmacologic antagonist of the CNS effects of benzodiazepines. "( Flumazenil: a new benzodiazepine antagonist.
Bayer, MJ; Bosse, GM; Hoffman, JR; Votey, SR, 1991
)
3.17
"Flumazenil is a highly effective specific competitive BZ antagonist which provides a safe means of rapidly attenuating or terminating BZ sedation."( The use of midazolam and flumazenil in diagnostic and short surgical procedures.
Whitwam, JG, 1990
)
1.3
"Flumazenil is a safe and effective benzodiazepine antagonist."( Flumazenil used for reversal of midazolam-induced sedation in endoscopy outpatients.
Bartelsman, JF; Sars, PR; Tytgat, GN,
)
2.3
"Flumazenil is a safe and effective benzodiazepine antagonist which makes it possible to reduce the recovery period in outpatients sedated sufficiently with benzodiazepines for gastroscopy."( Flumazenil used for antagonizing the central effects of midazolam and diazepam in outpatients.
Jensen, S; Kirkegaard, L; Knudsen, EB; Knudsen, L; Kruse, A, 1989
)
2.44
"Flumazenil is a potent-specific benzodiazepine receptor antagonist that has been shown to reverse CNS depressant effects mediated by benzodiazepine agonists. "( Flumazenil decreases the minimum alveolar concentration isoflurane in dogs.
Kanchuger, MS; Maneksha, FR; Poppers, PJ; Schwartz, AE; Sidhu, US, 1989
)
3.16
"Flumazenil appears to be a useful drug for the reversal of prolonged benzodiazepine sedation but repeated bolus doses or an infusion are needed if significant accumulation of benzodiazepines has occurred."( Reversal of prolonged sedation using flumazenil in critically ill patients.
Bodenham, A; Park, GR, 1989
)
1.27
"Flumazenil is an imidazobenzodiazepine that binds specifically to the central benzodiazepine receptor and antagonizes the actions of diazepam and other benzodiazepines. "( The effect of flumazenil on the recovery time of dental patients sedated with diazepam.
Kestenberg, SH; Toal, CB; Young, ER,
)
1.93
"Flumazenil (Ro 15-1788) is a specific benzodiazepine antagonist that can selectively prevent or abolish at the receptor level all centrally mediated effects of benzodiazepines. "( Drug interactions and clinical pharmacokinetics of flumazenil.
Klotz, U, 1988
)
1.97
"Flumazenil (Ro 15-1788) is a ligand of the benzodiazepine receptor (BZR) with high affinity, great specificity and minimal positive intrinsic efficacy, which reaches its sites of action within the CNS very rapidly after i.v. "( The preclinical pharmacology of flumazenil.
Haefely, W, 1988
)
2
"(1) Flumazenil is a highly specific benzodiazepine (BZ) antagonist. "( Clinical pharmacology of flumazenil.
Amrein, R; Hartmann, D; Hetzel, W; Lorscheid, T, 1988
)
1.14
"Flumazenil (Ro 15-1788) is a new benzodiazepine antagonist."( Midazolam infusion and the benzodiazepine antagonist flumazenil for sedation of intensive care patients.
Barzelai, E; Geller, E; Halpern, P; Lewis, MC; Nevo, Y; Silbiger, A; Sorkine, P, 1988
)
1.25
"Flumazenil (Ro 15-1788) is a specific benzodiazepine antagonist which can prevent or abolish selectively at the receptor level all centrally mediated effects of benzodiazepines. "( Pharmacokinetics and clinical use of flumazenil (Ro 15-1788).
Kanto, J; Klotz, U, 1988
)
1.99
"2. Flumazenil is a specific antagonist with a rapid onset of action."( [Postoperative reversal of loss of vigilance following midazolam with the use of the antagonist flumazenil (Ro 15-1788). A comparative study with a placebo and the use of EEG-power spectra].
Fournell, A; Freye, E, 1988
)
1.01
"Flumazenil is a specific benzodiazepine antagonist. "( Lack of effect of the benzodiazepine antagonist flumazenil (Ro 15-1788) on the performance of healthy subjects during experimentally induced ethanol intoxication.
Flückiger, A; Hartmann, D; Leishman, B; Ziegler, WH, 1988
)
1.97
"Flumazenil is a drug that should be included in the armamentarium of any emergency drug kit when benzodiazepines are used i.v."( The use of flumazenil as an antagonist to midazolam in intravenous sedation for dental procedures.
Hooper, PA; Rosenbaum, NL, 1988
)
1.39

Effects

Oral flumazenil has been proposed for long-term treatment but is not presently available on the market. It has been reported to reverse sedation from all three Z-drugs. Flumazanil has a similar binding affinity as Ro 15-4513 with an enzyme-flumazinil dissociation constant of 6.0 mM at pH 7.0.

ExcerptReferenceRelevance
"Flumazenil has a similar binding affinity as Ro 15-4513 with an enzyme-flumazenil dissociation constant of 6.0 mM at pH 7.0."( Inhibition and inactivation of horse liver alcohol dehydrogenase with the imidazobenzodiazepine Ro 15-4513.
Langeland, BT; McKinley-McKee, JS, 1994
)
1.01
"Flumazenil has been reported to reverse sedation from all three Z-drugs."( The clinical and forensic toxicology of Z-drugs.
Gunja, N, 2013
)
1.11
"Flumazenil has been reported to reverse the CNS effects of zolpidem."( Pediatric zolpidem ingestion demonstrating zero-order kinetics treated with flumazenil.
Carstairs, SD; Negus, E; Thornton, SL, 2013
)
1.34
"Flumazenil has been experimentally proven to produce an antagonism on acetaminophen's analgesic effect.The purpose of this study was to determine whether flumazenil antagonized the toxic effects of acetaminophen overdose in rats."( The effect of different doses of flumazenil on acetaminophen toxicity in rats.
Aksu, R; Bicer, C; Boyaci, A; Bozogluer, E; Madenoglu, H; Yazici, C, 2012
)
1.38
"Flumazenil has been reported to provoke panic attacks in patients with panic disorder (PD) but not in healthy controls."( A rapid high-pressure liquid chromatographic procedure for determination of flumazenil in plasma.
Baker, GB; Coupland, NJ; Rauw, GA; Zedkova, L,
)
1.08
"Flumazenil has no role in the routine treatment of coma unless the patient is known to not be benzodiazepine dependent and the overdose is known to result only from benzos--two very difficult requirements to verify in the back of an ambulance at 2 a.m."( No more coma cocktails. Using science to dispel myths & improve patient care.
Bledsoe, BE, 2002
)
1.04
"Flumazenil has a similar binding affinity as Ro 15-4513 with an enzyme-flumazenil dissociation constant of 6.0 mM at pH 7.0."( Inhibition and inactivation of horse liver alcohol dehydrogenase with the imidazobenzodiazepine Ro 15-4513.
Langeland, BT; McKinley-McKee, JS, 1994
)
1.01
"Flumazenil has been studied for a variety of indications, including as an antidote to benzodiazepine overdose and for awakening of comatose patients, reversal of sedation after surgery and in critically ill patients, and management of hepatic encephalopathy."( Flumazenil: a benzodiazepine antagonist.
Hoffman, EJ; Warren, EW, 1993
)
2.45
"Flumazenil has been shown to be effective in reversing benzodiazepine-induced sedation, but its ability to reverse benzodiazepine-induced respiratory depression is controversial."( Effect of flumazenil on benzodiazepine-induced respiratory depression.
Englander, FA; Naumann, TL; Shalansky, SJ, 1993
)
1.41
"Oral flumazenil has been proposed for long-term treatment but is not presently available on the market."( [Chronic hepatic encephalopathy treated by long-term intravenous administration of flumazenil in ambulatory care].
Frappa, B; Paolini, O; Péroux, JL; Rampal, P; Tran, A, 1996
)
0.97
"Flumazenil has been clinically described as an agent with few intrinsic properties, whose primary effect lies in its ability to reverse benzodiazepine-induced states. "( Dose-dependent effects of flumazenil on cognition, mood, and cardio-respiratory physiology in healthy volunteers.
Ayre, G; Girdler, NM; Moss, M; Neave, N; Reid, C; Scholey, AB; Thompson, JM; Wesnes, K, 2000
)
2.05
"Flumazenil has been studied for antagonism of the residual sedative effect of midazolam administered as a complement of loco-regional anesthesias. "( A clinical double-blind study of flumazenil, antagonist of benzodiazepines, in loco-regional anesthesia.
Bianchi, G; Stenier, P, 1992
)
2.01
"Flumazenil has only an inactive metabolite."( Pharmacology of Dormicum (midazolam) and Anexate (flumazenil).
Amrein, R; Hetzel, W, 1990
)
1.25
"Flumazenil has slight partial agonistic properties that can be seen as a built-in safety mechanism when used in reversing agonist effects and that may be of use in the treatment of epilepsies."( The preclinical pharmacology of flumazenil.
Haefely, W, 1988
)
1.28
"Flumazenil has been shown to readily antagonize the sedative, respiratory depressant, anxiolytic, muscle relaxant, anticonvulsant, amnestic, and anesthetic effects of the benzodiazepines; it appears to have tremendous potential for use in anesthesia, conscious sedation, and emergency medicine when available."( Reversal agents in sedation and anesthesia: a review.
Anderson, JA,
)
0.85

Actions

Flumazenil prompted an increase in sleep onset latency, a decrease in slow wave sleep and an increase of wakefulness. The drug reversed the increase in defensiveness produced by FG-7142 in a drug-dependent manner.

ExcerptReferenceRelevance
"Flumazenil prompted an increase in sleep onset latency, a decrease in slow wave sleep and an increase in wakefulness."( Flumazenil exerts intrinsic activity on sleep EEG and nocturnal hormone secretion in normal controls.
Guldner, J; Holsboer, F; Lauer, CJ; Meschenmoser, C; Pollmächer, T; Steiger, A, 1994
)
2.45
"Flumazenil reversed the increase in defensiveness produced by FG-7142 in a drug-dependent manner as described in Adamec (1998a)."( Evidence that NMDA-dependent limbic neural plasticity in the right hemisphere mediates pharmacological stressor (FG-7142)-induced lasting increases in anxiety-like behavior: study 3--the effects on amygdala efferent physiology of block of NMDA receptors p
Adamec, RE, 1998
)
1.02
"Flumazenil afforded lower MO consumption during the immediate postoperative period. "( Flumazenil potentiation of postoperative morphine analgesia.
Geller, E; Niv, D; Rudick, V; Weinbroum, AA; Weisenberg, M, 2000
)
3.19
"Flumazenil did not produce any significant pharmacological effect."( In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates.
Bottlaender, M; Brouillet, E; Chavoix, C; Dodd, RH; Fournier, D; Hantraye, P; Khalili-Varasteh, M; Mazière, M, 1991
)
1
"Flumazenil does not enhance fentanyl-induced respiratory depression."( [The effect of flumazenil on alfentanyl-induced respiratory depression].
Behne, M, 1991
)
1.36
"Flumazenil leads to an increase of negative sensations in respect to an invers agonizing effect."( [Flumazenil (Anexate): an antagonist of benzodiazepines. Its pharmacopsychologic significance and role in traffic medicine].
Joachim, H; Zimmer, G, 1990
)
1.91
"Flumazenil did produce inconsistent and relatively small changes in Ra."( The rate of CSF formation, resistance to reabsorption of CSF, and aperiodic analysis of the EEG following administration of flumazenil to dogs.
Artru, AA, 1990
)
1.21
"Flumazenil may increase the flexibility and safety of this mode of sedation."( Midazolam infusion and the benzodiazepine antagonist flumazenil for sedation of intensive care patients.
Barzelai, E; Geller, E; Halpern, P; Lewis, MC; Nevo, Y; Silbiger, A; Sorkine, P, 1988
)
1.25

Treatment

Pre-treatment with flumazenil treatment reversed benzodiazepine tolerance and restored neuroprotection by post-ischaemic diazepam. Pretreatment with 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxam ide did not reduce the acid secretion induced by DMCM.

ExcerptReferenceRelevance
"Flumazenil treatment can improve with - drawal symptoms and leads to higher abstinence rates."( The problems of long-term treatment with benzodiazepines and related substances.
Hoffmann, K; Janhsen, K; Roser, P, 2015
)
1.14
"Flumazenil pretreatment decreased the prolongation of seizure latency induced by both diazepam and isopulegol, although it was not able to reverse the latency and protection percent for mortality."( Effects of isopulegol on pentylenetetrazol-induced convulsions in mice: possible involvement of GABAergic system and antioxidant activity.
de Aquino Neto, MR; de Lavor, EP; de Sousa, DP; de Sousa, FC; de Sousa, HL; de Vasconcelos, PF; Macêdo, DS; Moura, BA; Silva, MA; Silva, MI; Vasconcelos, SM, 2009
)
1.07
"Flumazenil pretreatment of elderly ECT patients with declining seizure quality and inadequate clinical response in the setting of repeated treatments may represent a novel strategy for managing such patients. "( Flumazenil pretreatment in benzodiazepine-free patients: a novel method for managing declining ECT seizure quality.
Azner, Y; Reti, IM; Schiavi, A; Torres, J; Vaidya, P; Yi, J, 2012
)
3.26
"Flumazenil treatment before BCAO reduced ischaemic neuronal damage exacerbated by benzodiazepine tolerance (P<0.05), and restored neuroprotection by post-ischaemic diazepam (P<0.05), the effect of which was reduced by benzodiazepine tolerance (P<0.05)."( Effects of diazepam and flumazenil on forebrain ischaemia in a rat model of benzodiazepine tolerance.
Furuya, H; Inoue, S; Iwata, M; Kawaguchi, M, 2012
)
1.41
"Flumazenil treatment did not affect recovery."( Effectiveness of antagonists for tiletamine-zolazepam/xylazine immobilization in female white-tailed deer.
Doherty, T; Miller, BF; Miller, KV; Muller, LI; Osborn, DA; Warren, RJ, 2004
)
1.04
"Flumazenil treatment of the amygdala during the first 2 withdrawals blocked the development of sensitized anxiety seen during a third withdrawal. "( The amygdala regulates the antianxiety sensitization effect of flumazenil during repeated chronic ethanol or repeated stress.
Angel, RA; Breese, GR; Knapp, DJ; Navarro, M; Overstreet, DH, 2007
)
2.02
"Flumazenil 10 mg/kg pretreated group showed a different pattern of distribution of hexobarbital into the tested brain regions indicating a pharmacokinetic interaction."( Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat.
Korkmaz, S; Ljungblad, E; Wahlström, G, 1995
)
1.34
"2. Flumazenil treatment decreased the rate of ultrasonic vocalization in 15-day old male pups removed from their nest."( Behavioral changes produced in rats by developmental exposure to flumazenil, a benzodiazepine receptor antagonist.
Cagiano, R; Cuomo, V; De Salvia, MA; Giustino, A; Lacomba, C, 1993
)
1.04
"Flumazenil-treated patients also performed significantly better on the Finger-to-Nose Test and the recall of pictures shown at the 5-minute assessment."( Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study. The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.
,
)
1.11
"Flumazenil treatment of ethanol-dependent mice 14 hr before isolation of brain membrane vesicles partially reversed the augmentation of Ro15-4513 inhibition of muscimol-stimulated 36Cl- uptake in vitro."( Reversal of alcohol dependence and tolerance by a single administration of flumazenil.
Buck, KJ; Harris, RA; Heim, H, 1991
)
1.23
"Flumazenil-treated patients were significantly more alert than those who received placebo at 10 min, 30 min, 1 h and 2 h (P less than 0.001 in all instances)."( The value of flumazenil in the reversal of midazolam-induced sedation for upper gastrointestinal endoscopy.
Ashley, N; Dundas, CR; Dunk, AA; Hudson, M; Mowat, G; Norton, AC, 1990
)
1.37
"This flumazenil treatment produced a slight attenuation in the degree of tolerance to midazolam on day 6, suggesting that receptor sensitivity to the benzodiazepine agonist may have partially reset."( Behavioral differentiation of benzodiazepine ligands after repeated administration in baboons.
Cook, JM; Griffiths, RR; Sannerud, CA, 1989
)
0.73
"Pretreatment by flumazenil could inhibit the effect of Citrullus colocynthis on latency of seizure to some extent and administration of naloxone significantly inhibited changes in latency and duration of seizure produced by Citrullus colocynthis This study showed that Citrullus colocynthis has significant anticonvulsant effect in pentylenetetrazole-induced seizures in mice, and these effects may be related to its effect on γ-aminobutyric acid-ergic and opioid systems."( Anticonvulsant Activity of Hydroalcoholic Extract of Citrullus colocynthis Fruit: Involvement of Benzodiazepine and Opioid Receptors.
Mehrzadi, S; Motevalian, M; Pur, SA; Shojaii, A, 2016
)
0.77
"Pretreatment with flumazenil abolished the somnogenic effects and activation of the VLPO neurons by honokiol."( Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice.
Chen, CR; Fan, K; Hou, YP; Huang, ZL; Qu, WM; Sun, Y; Urade, Y; Yue, XF, 2012
)
0.7
"Pretreatment with flumazenil suppressed the anticonvulsant effects of vitexin during the onset of both the seizures."( Neuroprotective effects of vitexin, a flavonoid, on pentylenetetrazole-induced seizure in rats.
Abbasi, E; Nassiri-Asl, M; Shafeei, M; Sheikhi, M, 2012
)
0.7
"Pre-treatment with flumazenil treatment reversed benzodiazepine tolerance and restored neuroprotection by post-ischaemic diazepam."( Effects of diazepam and flumazenil on forebrain ischaemia in a rat model of benzodiazepine tolerance.
Furuya, H; Inoue, S; Iwata, M; Kawaguchi, M, 2012
)
1
"The treatment with flumazenil completely abolished the decrease in the metabolite (P < 0.05)."( Flumazenil-induced improvement of the central dopaminergic system in rats with acute hepatic failure.
Adachi, N; Arai, T; Liu, K; Yano, M, 2005
)
2.09
"Pretreatment with flumazenil (1.0 mg/kg) blocked the stimulus effects of the training dose of DMCM and produced a shift to the right of the DMCM generalization curve."( Discriminative stimulus properties of the benzodiazepine receptor inverse agonist methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM).
Kirby, LG; Lucki, I; Rowan, GA; Smith, RL, 1994
)
0.61
"Pretreatment with flumazenil (0.01-1.0 mg/kg) resulted in a dose-related parallel shift to the right in the dose-response function for PB-appropriate responding in all monkeys for all three BZs."( Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline.
Nader, MA; Woolverton, WL, 1995
)
0.85
"Pretreatment with flumazenil, which is a benzodiazepine receptor antagonist, reduced the acid secretion induced by diazepam, but pretreatment with 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxam ide, which is a peripheral benzodiazepine receptor antagonist, did not reduce the acid secretion induced by diazepam."( Stimulatory effect of diazepam on gastric acid secretion in the continuously perfused stomach in rats under urethane anesthesia.
Lin, WC, 1997
)
0.62
"Pre-treatment with flumazenil (0.1 or 0.2 mg kg(-1)) significantly decreased the hypnotic dose of propofol compared to the control group (9.3+/-0.39 [8.5-10.0] or 9.0+/-0.28 [8.5-9.6] vs. "( High-dose flumazenil potentiates the hypnotic activity of propofol, but not that of thiopental, in ddY mice.
Adachi, YU; Higuchi, H; Satoh, T; Watanabe, K, 2001
)
1.04
"Pretreatment with flumazenil (0.3-1.0 mg/kg) antagonized the anticonflict and response rate-decreasing effects of all three agonists."( Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.
Bergman, J; Cook, JM; Cox, ED; Paronis, CA, 2001
)
0.63
"Pretreatment with flumazenil alone changed neither cumulative convulsant doses nor plasma concentrations of lidocaine at the onset of convulsions."( Effects of flumazenil on intravenous lidocaine-induced convulsions and anticonvulsant property of diazepam in rats.
Arakawa, K; Benson, KT; Goto, H; Yokoyama, M, 1992
)
1
"Treatment with flumazenil increased alertness 2 minutes after the procedure, and was associated with a significantly higher arterial oxygen saturation at 15 minutes."( The effects of flumazenil on alertness and hypoxia in elderly patients after ERCP.
Bibbey, D; Green, JR; Haines, DJ, 1992
)
0.98
"Pretreatment with flumazenil blocked the CDP-elicited release of CS."( Effects of chlordiazepoxide, flumazenil and DMCM on plasma catecholamine and corticosterone concentrations in rats.
De Boer, SF; Slangen, JL; Van der Gugten, J, 1991
)
0.9
"Treatment with flumazenil during benzodiazepine agonist administration, or even in the period after the last dose, can prevent or reverse this efficacy shift as indicated by a lack of sensitization to inverse agonists."( Pharmacological mechanisms of benzodiazepine withdrawal.
Nutt, DJ, 1990
)
0.62
"When treated with flumazenil all signs of encephalopathy abated in spite of an unrestricted dietary intake of protein."( Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil.
Ferenci, P; Gangl, A; Grimm, G; Meryn, S, 1989
)
0.82

Toxicity

Administration of flumazenil resulted in a safe shortening of the recovery period and offers the possibility for substantial savings in time, space, and nurse resources. Thirty-seven of 107 patients (35%) experienced a total of 56 adverse events.

ExcerptReferenceRelevance
" We conclude that flumazenil is safe when administered in relatively high doses to patients with ischaemic heart disease who have not received benzodiazepines."( Safety of rapid administration of flumazenil in patients with ischaemic heart disease.
Croughwell, ND; Goodman, DK; Kasson, BJ; Reves, JG; Will, CJ, 1990
)
0.89
" There were no serious adverse effects related to the study drug, and minor adverse effects were similar for the 2 groups."( Safety and efficacy of flumazenil in reversing conscious sedation in the emergency department. Emergency Medicine Conscious Sedation Study Group.
Chudnofsky, CR, 1997
)
0.61
"Flumazenil is safe and efficacious in reversing midazolam-induced sedation in ED patients given a combination of fentanyl and midazolam to facilitate the performance of a short, painful procedure."( Safety and efficacy of flumazenil in reversing conscious sedation in the emergency department. Emergency Medicine Conscious Sedation Study Group.
Chudnofsky, CR, 1997
)
2.05
" Thirty-seven of 107 patients (35%) experienced a total of 56 adverse events, most of which were considered to be unrelated to flumazenil administration."( Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The Flumazenil Pediatric Study Group.
Albers, G; Burkhart, K; Hoffman, J; Kelley, M; Liebelt, E; Massarella, J; McCubbin, MM; Shannon, M, 1997
)
0.81
"Flumazenil promptly and effectively reverses the central nervous system depressant effects of midazolam in children undergoing conscious sedation, with no significant adverse effects."( Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The Flumazenil Pediatric Study Group.
Albers, G; Burkhart, K; Hoffman, J; Kelley, M; Liebelt, E; Massarella, J; McCubbin, MM; Shannon, M, 1997
)
2.05
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"To identify clinically significant drug interactions and potentially related adverse drug events associated with the use of midazolam."( Midazolam-related drug interactions: detection of risk situations to the patient safety in a brazilian teaching hospital.
de Freitas, O; Kawano, DF; Pereira, LR; Sankarankutty, AK; Ueta, J, 2009
)
0.35
" Patients' orders were checked for the presence of clinically significant drug interactions and for the inclusion and discontinuation of potential trigger medications for adverse drug events related to midazolam."( Midazolam-related drug interactions: detection of risk situations to the patient safety in a brazilian teaching hospital.
de Freitas, O; Kawano, DF; Pereira, LR; Sankarankutty, AK; Ueta, J, 2009
)
0.35
" Analysis of inclusion and discontinuation of drugs demonstrated that the first order for opiates preceded the use of flumazenil in 31% of the cases and, except for tramadol, all opiates were discontinued after its administration, highlighting the potential of these drugs to act as triggers for adverse drug events."( Midazolam-related drug interactions: detection of risk situations to the patient safety in a brazilian teaching hospital.
de Freitas, O; Kawano, DF; Pereira, LR; Sankarankutty, AK; Ueta, J, 2009
)
0.56
"Midazolam-related drug interactions are not infrequent and may conduce to serious adverse drug events, including hypotension, respiratory depression, and arrest."( Midazolam-related drug interactions: detection of risk situations to the patient safety in a brazilian teaching hospital.
de Freitas, O; Kawano, DF; Pereira, LR; Sankarankutty, AK; Ueta, J, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Ivermectin is considered a very safe drug; however, there are reports of toxic effects in particularly sensitive populations or due to accidental overdose."( Central and peripheral neurotoxic effects of ivermectin in rats.
Nedeljkovic, JT; Trailovic, SM, 2011
)
0.37
"The purpose of this study was to determine whether flumazenil antagonized the toxic effects of acetaminophen overdose in rats."( The effect of different doses of flumazenil on acetaminophen toxicity in rats.
Aksu, R; Bicer, C; Boyaci, A; Bozogluer, E; Madenoglu, H; Yazici, C, 2012
)
0.91
"Administration of flumazenil resulted in a safe shortening of the recovery period and offers the possibility for substantial savings in time, space, and nurse resources."( Significant and safe shortening of the recovery time after flumazenil-reversed midazolam sedation.
de Jong, L; Kos-Foekema, HA; Mathus-Vliegen, EM, 2014
)
0.98
" For patients being treated for alcohol withdrawal, flumazenil can diagnose and treat benzodiazepine delirium without precipitating serious or life-threatening adverse events."( Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.
Adkins, AR; Burkhart, KK; Donovan, JW; Haggerty, DA; Hieger, MA; Moore, PW; Rasimas, JJ; Waskin, JA; Wert, Y, 2014
)
0.96
" Ongoing monitoring of this particular adverse event will be required with a sustained patient safety message to health services to maintain awareness of the issue and reduction in the number of midazolam-related errors."( Reducing risk of overdose with midazolam injection in adults: an evaluation of change in clinical practice to improve patient safety in England.
Flood, C; Lamont, T; Mansaray, M; Marsh, R; Matthew, L; Patel, B, 2015
)
0.42
" Serious adverse events (SAEs) including seizures and cardiac arrhythmias have been reported in patients treated with flumazenil, and the clinical advantage of flumazenil treatment has been questioned."( Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses of Randomised Trials.
Graudal, N; Jürgens, G; Ladekarl, MB; Penninga, EI, 2016
)
0.93
"The objective of the study is to assess adverse events and clinical outcomes of flumazenil administration in known and suspected BZD overdose in an ED at a tertiary academic medical center."( Lack of adverse effects from flumazenil administration: an ED observational study.
Cumpston, K; Nguyen, TT; Rose, SR; Troendle, M; Wills, BK, 2015
)
0.94
"Though uncommon, medical emergencies in the dental office are harrowing occurrences that can be the result of adverse drug reactions."( Pharmacological Reversal Agents in Dental Practice: Keys to Patient Safety.
Donaldson, M; Goodchild, JH,
)
0.13
" The time of stay in the recovery room and adverse events were reviewed through the nursing records."( Efficacy and safety of flumazenil injection for the reversal of midazolam sedation after elective outpatient endoscopy.
Kim, JH; Lee, SP; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2018
)
0.79
" No significant differences were found in the number of patients with pain (VAS ≥1), adverse events and discomfort between the two groups."( Efficacy and safety of flumazenil injection for the reversal of midazolam sedation after elective outpatient endoscopy.
Kim, JH; Lee, SP; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2018
)
0.79
"The time in the recovery room after flumazenil administration was significantly shortened, and the use of the drug did not increase the risk of adverse events or discomfort."( Efficacy and safety of flumazenil injection for the reversal of midazolam sedation after elective outpatient endoscopy.
Kim, JH; Lee, SP; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2018
)
1.07
"Administration of flumazenil is safe in benzodiazepine-poisoned patients with appropriate indications."( Protective effect of flumazenil infusion in severe acute benzodiazepine toxicity: a pilot randomized trial.
Ebrahimi, S; Hassanian-Moghaddam, H; Razavizadeh, AS; Zamani, N; Ziaeefar, P, 2021
)
1.27
" Since the observed effects were reversed by flumazenil and no side effect on the memory and muscle strength was reported, modulation of the α1-containing GABA-A receptors could be proposed as one of the involved mechanisms."( Sedative-hypnotic, anxiolytic and possible side effects of Salvia limbata C. A. Mey. Extracts and the effects of phenological stage and altitude on the rosmarinic acid content.
Behzad, S; Faizi, M; Jahani, R; Saffariha, M; Toufan Tabrizi, N, 2022
)
0.98
"1 mg/minute) to avoid complications or withhold the administration with development of first signs of adverse effects."( Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes.
Hassanian-Moghaddam, H; Zamani, N, 2022
)
0.72
"Lethal intestinal tissue toxicity is a common side effect and a dose-limiting factor in chemoradiotherapy."( Inhibition of GABAA receptors in intestinal stem cells prevents chemoradiotherapy-induced intestinal toxicity.
Chen, D; Guo, W; Hu, H; Jiang, W; Li, J; Li, Y; Liu, H; Mu, K; Ning, N; Yu, X; Zhang, C; Zheng, J; Zhou, Y, 2022
)
0.72
" Any adverse events were recorded."( Efficacy and safety of remimazolam tosilate versus propofol in patients undergoing day surgery: a prospective randomized controlled trial.
Huang, J; Liu, M; Luo, W; Miao, C; Sun, M; Wan, J; Xia, L; Xiong, W; Xu, P; Zhang, J; Zhang, X; Zhang, Z; Zhong, J, 2023
)
0.91

Pharmacokinetics

The objectives of the study were to develop a population pharmacokinetic model for (11)C-flumazenil at tracer concentrations. To assess the effects of patient-related covariates and to derive an optimal sampling protocol for clinical use.

ExcerptReferenceRelevance
"The pharmacokinetic and pharmacodynamic interaction between the benzodiazepine agonist midazolam and antagonist flumazenil was quantified in vivo in rats, using effect parameters derived from aperiodic EEG analysis."( In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil.
Danhof, M; Mandema, JW; Tukker, E, 1992
)
0.7
")], a short half-life (45."( Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction.
Butterworth, RF; Giguère, JF; Lavoie, J; Pomier-Layrargues, G; Willems, B, 1989
)
0.28
"The pharmacodynamic interaction between midazolam and the specific benzodiazepine antagonist Ro 15-1788 has been investigated in six healthy male volunteers."( Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans.
Klotz, U; Ludwig, L; Reimann, IW; Ziegler, G, 1985
)
0.27
" The correlation between receptor occupancy and the pharmacodynamic actions of these drugs in blocking pentylenetetrazol seizures and inducing rotarod ataxia indicated that ED50 for these effects occurred at receptor occupancy of 30 to 60% for both drugs."( Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions.
Greenblatt, DJ; Miller, LG; Paul, SM; Shader, RI, 1987
)
0.27
"During clinical pharmacology studies with the benzodiazepine antagonist Ro 15-1788 the pharmacokinetic characteristics of high intravenous doses (20 and 40 mg) and of an oral dose (200 mg) were examined in six healthy male volunteers."( Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.
Guentert, TW; Roncari, G; Ziegler, WH, 1986
)
0.27
" This can be characterised either by the short half-life (0."( Pharmacokinetics and clinical use of flumazenil (Ro 15-1788).
Kanto, J; Klotz, U, 1988
)
0.55
" Applicability of the method is demonstrated by a pharmacokinetic study in a normal volunteer who received 10 mg Ro 15-1788 intravenously."( Determination of Ro 15-1788, a benzodiazepine antagonist, in human plasma by gas-liquid chromatography with nitrogen-phosphorus detection. Application to single-dose pharmacokinetic studies.
Abernethy, DR; Arendt, RM; Greenblatt, DJ; Lauven, PM, 1983
)
0.27
" Application of the methods to pharmacokinetic studies in the rat found the elimination half-life of Ro 15-1788 from rat brain to be 16 min."( Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat.
Abernethy, DR; File, SE; Greenblatt, DJ; Lister, RG, 1984
)
0.27
" In sessions 2 and 3, a computer-controlled infusion of midazolam with individual volunteer pharmacokinetic data was administered, targeting a plasma concentration corresponding to a light or deep level of sedation (20% or 80% of the maximal midazolam electroencephalographic effect) for a period of 210 minutes."( Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam.
Egan, TD; Egan, TE; Fiset, P; Lemmens, HL; Shafer, SL; Stanski, DR, 1995
)
0.53
" To determine whether there are parallel or divergent rates of elimination of the two drugs between individuals, the pharmacokinetic profiles of midazolam and flumazenil were studied simultaneously in 12 adult male volunteers."( Midazolam and flumazenil pharmacokinetics and pharmacodynamics following simultaneous administration to human volunteers.
Gin, T; Oh, TE; Short, TG; Tam, YH; Tan, P; Young, KK, 1994
)
0.85
" ND and parent OX have similar pharmacokinetic profiles."( Pharmacokinetics of nordiazepam in physical dependence and precipitated abstinence in dogs.
Martin, WR; Sloan, JW; Wala, EP, 1993
)
0.29
" Midazolam data were consistent with a three-compartment model with a mean (SD) elimination half-life of 107 (30) min, total body clearance of 15."( Pharmacokinetics of flumazenil and midazolam.
Brown, AG; Chan, K; Jones, RD; Mya, GH; Roulson, CJ; Smith, ID, 1993
)
0.61
" The anticonvulsant effect at low midazolam concentration was characterized on basis of the sigmoid E maximal effect pharmacodynamic model."( Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect.
Arends, RH; Bomers, AM; Danhof, M; Hoogerkamp, A; Mandema, JW; Voskuyl, RA, 1996
)
0.29
" We describe the first set of experiments which directly measure agonist-induced changes in both pharmacodynamic effects and pharmacokinetic parameters simultaneously and which demonstrate the feasibility of these studies in man."( Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo.
Bloomfield, PM; Cunningham, VJ; Gunn, RN; Malizia, AL; Nutt, DJ; Waters, SH; Wilson, SJ, 1996
)
0.29
"The purpose of this study is to evaluate the central benzodiazepine (BZP) receptor binding of iomazenil (IMZ) by pharmacokinetic analysis and to establish a methodology for the diagnosis of CNS disorders with abnormalities in BZP receptor binding."( Pharmacokinetic analysis of benzodiazepine receptor binding of [123I]iomazenil in human brain.
Iga, T; Ito, K; Katashima, M; Kojima, Y; Kotaki, H; Momose, T; Sasaki, Y; Sawada, Y; Yamamoto, K, 1997
)
0.3
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" Finally, as a pharmacodynamic readout the benzodiazepine binding site occupancy was determined in rats (0."( Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417.
Atack, JR; Scott-Stevens, P; Sohal, B; Worboys, P, 2005
)
0.33
"Abstinent male alcohol dependent subjects underwent [11C]flumazenil PET to measure occupancy of BDZ receptors by midazolam whilst recording its pharmacodynamic effects on behavioural and physiological measures."( GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study.
Brooks, DJ; Cunningham, VJ; Feeney, A; Lingford-Hughes, AR; Nutt, DJ; Stevenson, B; Wilson, SJ, 2005
)
0.8
"The objectives of the study were to develop a population pharmacokinetic model for (11)C-flumazenil at tracer concentrations, to assess the effects of patient-related covariates and to derive an optimal sampling protocol for clinical use."( Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations.
Franssen, EJ; Greuter, HN; Huitema, AD; Lammertsma, AA; Swart, EL; van Loenen, AC; van Rij, CM, 2005
)
0.81
"A population pharmacokinetic model was developed using nonlinear mixed effects modelling (NONMEM) with data obtained from 51 patients with either depression or epilepsy."( Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations.
Franssen, EJ; Greuter, HN; Huitema, AD; Lammertsma, AA; Swart, EL; van Loenen, AC; van Rij, CM, 2005
)
0.59
" Mean population pharmacokinetic parameters (percent coefficient of variation) were: CL 1530 mL min(-1) (6."( Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations.
Franssen, EJ; Greuter, HN; Huitema, AD; Lammertsma, AA; Swart, EL; van Loenen, AC; van Rij, CM, 2005
)
0.59
"Following an injection of [C-11]FMZ (dose range: 1-2,000 mug) to 21 rats, concentration time curves of FMZ in brain (using PET) and blood (using HPLC-UV) were analyzed simultaneously using a population pharmacokinetic (PK) model, containing expressions to describe the time course of the plasma concentration (including distribution to the body), the brain distribution, and the specific binding within the brain."( Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography.
Boellaard, R; Danhof, M; Lammertsma, AA; Liefaard, LC; Molthoff, CF; Ploeger, BA; Voskuyl, RA,
)
0.13
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Diazepam in doses of 10 mg/kg and 15 mg/kg produced long-time and reproducible pharmacodynamic effects."( [Pharmacodynamic and pharmacokinetic effects of flumazenil and theophylline application in rats acutely intoxicated by diazepam].
Dordević, S; Jaćević, V; Jović-Stosić, J; Kilibarda, V; Potrebić, O; Segrt, Z; Vucinić, S; Vukcević-Perković, N, 2009
)
0.61
" These effects are a result of different mechanisms of their action, longer half-life of theophylline in relation to that of flumezenil and presumably the diuretic effect of theophylline."( [Pharmacodynamic and pharmacokinetic effects of flumazenil and theophylline application in rats acutely intoxicated by diazepam].
Dordević, S; Jaćević, V; Jović-Stosić, J; Kilibarda, V; Potrebić, O; Segrt, Z; Vucinić, S; Vukcević-Perković, N, 2009
)
0.61

Compound-Compound Interactions

The study was conducted in selectively bred alcohol-preferring (P) rats. It provided a two-bottle choice test between ethanol (EtOH) (10% v/v), and a palatable saccharin (0.0 mg/kg) alone and in combination with Ro15-1788, (flumazenil) (8.3-10 mg/ kg) and CGS 8216 (20 mg/ kilograms)

ExcerptReferenceRelevance
"0 mg/kg), and Ro15-4513 in combination with Ro15-1788 on the time course of ETOH self-administration."( Ethanol self-administration in deprived rats: effects of Ro15-4513 alone, and in combination with flumazenil (Ro15-1788).
Colker, RE; Domangue, KR; Hicks, LH; June, HL; June, PL; Lewis, MJ; Perry, LE, 1992
)
0.5
"The beta-carboline FG 7142 was studied alone and in combination with Ro 15-1788, CGS 8216 and lorazepam in squirrel monkeys trained to respond under a fixed-interval (FI) schedule of food presentation."( Behavioral studies with the beta-carboline FG 7142 combined with related drugs in monkeys.
Wettstein, JG, 1989
)
0.28
"0 mg/kg) alone and in combination with Ro15-1788, (flumazenil) (8."( Ethanol self-administration in freely feeding and drinking rats: effects of Ro15-4513 alone, and in combination with Ro15-1788 (flumazenil).
Hughes, RW; June, HL; Lewis, MJ; Spurlock, HL, 1994
)
0.75
"3-10 mg/kg) alone and in combination with flumazenil (0."( Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline.
Nader, MA; Woolverton, WL, 1995
)
0.79
"30 mg/kg) alone, and in combination with the BDZ receptor antagonists flumazenil, ZK 93426, and CGS 8216 (20 mg/kg) in selectively bred alcohol-preferring (P) rats provided a two-bottle choice test between ethanol (EtOH) (10% v/v), and a palatable saccharin (0."( Effects of the benzodiazepine inverse agonist RO19-4603 alone and in combination with the benzodiazepine receptor antagonists flumazenil, ZK 93426 and CGS 8216, on ethanol intake in alcohol-preferring (P) rats.
Cason, CR; Cox, R; Duemler, SE; Greene, TL; Hite, ML; June, HL; Li, TK; Lumeng, L; Mellon-Burke, J; Murphy, JM; Torres, L; Williams, JA, 1996
)
0.73
" GHB is frequently combined with other recreational drugs although these interactions are not well characterised."( Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry.
McGregor, IS; van Nieuwenhuijzen, PS, 2009
)
0.35
" We employed aEEG in combination with conventional EEG in an 11-year old boy presenting with clusters of seizures and were able to accurately evaluate the frequency of seizures in real time."( A case of frontal lobe epilepsy in which amplitude-integrated EEG combined with conventional EEG was useful for evaluating clusters of seizures.
Ishikawa, N; Kobayashi, M; Kobayashi, Y, 2010
)
0.36

Bioavailability

This study was performed to determine the bioavailability and local tissue toxicological safety of flumazenil (Romazicon) when administered by oral submucosal (SM) as opposed to intravenous (i.e., IV) After oral administration flumzenil was rapidly absorbed; however, theBioavailability was low (28 +/- 4%) and variable.

ExcerptReferenceRelevance
" After oral administration flumazenil was rapidly absorbed; however, the bioavailability was low (28 +/- 4%) and variable."( Stability and pharmacokinetics of flumazenil in the rat.
Danhof, M; Gubbens-Stibbe, JM; Mandema, JW, 1991
)
0.86
" 10%) and its bioavailability following oral administration is about 22%."( The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs.
Martin, WR; Pruitt, TA; Sloan, JW; Wala, EP, 1990
)
0.63
" Consequently, it could be anticipated that hepatic disease affects the elimination and oral bioavailability of flumazenil."( Flumazenil disposition and elimination in cirrhosis.
Janssen, U; Klotz, U; Maier, K; von Gaisberg, U; Walker, S, 1989
)
1.93
" Following oral administration flumazenil is rapidly absorbed (peak concentrations are achieved after 20 to 90 minutes), but bioavailability is low (16%) due to significant presystemic elimination."( Pharmacokinetics and clinical use of flumazenil (Ro 15-1788).
Kanto, J; Klotz, U, 1988
)
0.83
" In 26% (elderly) and 23% (young), the absolute bioavailability of flumazenil was very similar."( Flumazenil kinetics in the elderly.
Roncari, G; Timm, U; Weber, W; Zell, M; Zumbrunnen, R, 1993
)
1.96
" dose of bupivacaine, C max, Vd, Cl and AUC were not significantly modified by flumazenil; even if T max was shown to be significantly shorter when flumazenil was associated, bupivacaine bioavailability did not seem to be modified and thus may not be involved in the explanation of previously reported increasing bupivacaine-induced mortality by flumazenil."( Lack of bupivacaine kinetic changes induced by flumazenil in mice.
Bruguerolle, B; Lorec, AM, 1993
)
0.77
" Administered orally, it has a low bioavailability and the preferred route is intravenous."( Pharmacology of flumazenil.
Amrein, R; Whitwam, JG, 1995
)
0.64
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"This study was performed to determine the bioavailability and local tissue toxicological safety of flumazenil (Romazicon) when administered by oral submucosal (SM) as opposed to intravenous (i."( Comparative pharmacokinetics of submucosal vs. intravenous flumazenil (Romazicon) in an animal model.
Arheart, KL; Kahn, MA; Mandrell, TD; Oliver, FM; Randolph, MM; Sweatman, TW; Unkel, JH,
)
0.59
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Flumazenil (Ro 15-1788) administration caused a parallel shift to the right of the dose-response curve for midazolam spinal analgesia. In addition, as a bridging study, lorazepam occupancy was measured using [(3)H]flumazinil in vivo binding in rats anesthetized and dosed under micro-PET conditions.

ExcerptRelevanceReference
" For zolpidem, receptor binding was reduced in cortex without a dose-response effect and no effect was observed on cerebellar binding."( Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone.
Byrnes, JJ; Greenblatt, DJ; Miller, LG, 1992
)
0.28
" Using a cumulative dosing procedure, PTZ substituted for PTZ, and MDZ, chlordiazepoxide and diazepam (DZP) substituted for MDZ, in a dose-dependent manner."( Tolerance, cross-tolerance and withdrawal in rats made dependent on diazepam.
Boone, MS; Emmett-Oglesby, MW; Pugh, SL, 1992
)
0.28
" In Experiment 1, using a cumulative dosing paradigm, the effect of DZ on noise potentiation was found to be dose related."( Modulation of noise-potentiated acoustic startle via the benzodiazepine--gamma-aminobutyric acid receptor complex.
Bitran, D; Ison, JR; Kellogg, CK; Sullivan, AT, 1991
)
0.28
" Comparison of the dose-response curves demonstrated a difference in the intensity of the stimulus effects."( The discriminative stimulus effects of diazepam in rats at two training doses.
Franklin, SR; Tang, AH, 1991
)
0.28
"Dogs dosed chronically (4-7 weeks) with oral flunitrazepam (7."( A comparison of the physical dependence inducing properties of flunitrazepam and diazepam.
Martin, WR; Sloan, JW; Wala, EP, 1991
)
0.28
" The drug was administered intramuscularly in ten dogs at a dosage of 10 mg/kg bwt of tiletamine and 10 mg/kg bwt of zolazepam and tested for its effects on hemodynamics, respiration, and the antagonistic effect of flumazenil."( [Anesthesia in dogs with the combination preparation Tilest 500].
Hess, L, 1991
)
0.47
" On this basis, dosage recommendations for midazolam in total intravenous anaesthesia techniques are possible, aiming at hypnotic plasma concentrations of at least 250 ng."( Anaesthesia techniques for midazolam and flumazenil--an overview.
Kulka, PJ; Lauven, PM, 1990
)
0.54
" Cumulative dose-response curves were determined for pancuronium, and ED50 was calculated from each of the 5 curves."( [The effect of RO15-1788 on the interaction between pancuronium and diazepam].
Amaki, Y; Hajiri, H; Kaneko, M; Kobayashi, K; Kumagai, M; Shudo, Y, 1990
)
0.28
" An inactive dose of intrathecally-administered midazolam (20 micrograms) produced a leftward shift in the dose-response curve for intrathecally administered morphine, in the thermal antinociceptive tests."( Interaction of midazolam and morphine in the spinal cord of the rat.
Sabbe, MB; Stevens, CW; Yaksh, TL; Yanez, A, 1990
)
0.28
" Flumazenil (Ro 15-1788) administration caused a parallel shift to the right of the dose-response curve for midazolam spinal analgesia."( On the mechanism by which midazolam causes spinally mediated analgesia.
Edwards, M; Gent, JP; Goodchild, CS; Serrao, JM, 1990
)
1.19
") shifted the dose-response curve of FG 7142 progressively to the right indicating pharmacological antagonism at benzodiazepine recognition sites."( Behavioral studies with the beta-carboline FG 7142 combined with related drugs in monkeys.
Wettstein, JG, 1989
)
0.28
" The two patients with coma of unknown origin demonstrated no clinical response to flumazenil at a dosage of 2 mg."( [The efficacy of the benzodiazepine antagonist flumazenil (Ro 15-1788) based on the EEG of mechanically ventilated intensive care patients].
Kulka, PJ; Lauven, PM; Rommelsheim, K; Schwilden, H, 1989
)
0.76
" A phase-response curve and a dose-response curve were measured to determine the effects of a single intraperitoneal injection of midazolam on the circadian clock of hamsters free-running in constant light."( Midazolam, a short-acting benzodiazepine, resets the circadian clock of the hamster.
Turek, FW; Wee, BE, 1989
)
0.28
" When platelets were pretreated with either BDZR ligand, and then exposed to various concentrations of WEB 2086, there was no alteration of the dose-response relationship of the hetrazepine on PAF-induced aggregation, as reflected by threshold concentration, ED50, or maximum inhibition seen with WEB 2086."( The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
Griffin, K; Hong, T; Levy, JV, 1989
)
0.28
" Dosage requirements for anesthetic agents are shown."( Fentanyl-midazolam-flumazenil anesthesia for induced abortion.
Garamvölgyi, G; Hamar, O; Kálmán, A, 1989
)
0.61
" The dose-response curve of the GABA-evoked catecholamine release was shifted to the left by midazolam without affecting the maximal response to GABA."( Benzodiazepines facilitate the stimulatory action of gamma-aminobutyric acid (GABA) on basal and veratridine-evoked catecholamine release from cultured bovine adrenal chromaffin cells.
Dohi, T; Kitayama, S; Morita, K; Tsujimoto, A,
)
0.13
" A dose-response curve obtained from generations 6 and 7 indicates a 9- to 14-fold difference in dose required to obtain similar effects in the two lines."( Mouse lines selected for genetic differences in diazepam sensitivity.
Crabbe, JC; Gallaher, EJ; Gionet, SE; Hollister, LE, 1987
)
0.27
" Enhancement of submaximal GABA responses by benzodiazepines was demonstrated using a multibarrel pipette to construct complete benzodiazepine dose-response curves for single cells in culture."( Benzodiazepine interactions with GABAA receptors on chick ciliary ganglion neurons.
Berg, DK; McEachern, AE, 1988
)
0.27
" The indication to treat unwanted central effects of benzodiazepines either with flumazenil or with physostigmine after anaesthesia should be restricted to cases of distinctly prolonged sedation after adequate dosage or adverse side effects."( Flumazenil (Ro 15-1788) and physostigmine.
Lauven, PM; Stoeckel, H, 1988
)
1.94
" Complete dose-response curves were carried out on individual neurons, reducing error introduced by cell-to-cell variability."( Modulation of neurotransmitter action: control of the gamma-aminobutyric acid response through the benzodiazepine receptor.
Chan, CY; Farb, DH, 1985
)
0.27
" According to the benzodiazepine dosage and the rapid plasma concentration decline of flumazenil, in some cases a resedation could be observed."( [Antagonism of the effects of benzodiazepines using flumazenil (Ro 15-1788)].
Kulka, P; Lauven, PM, 1988
)
0.75
"5 mg/kg diazepam-morphine dose-response curve."( The possible modulation of morphine analgesia by the supramolecular GABA receptor complex.
Ayhan, IH; Palaoglu, O, 1986
)
0.27
" However, the dosage of Ro15-1788 required for these actions was at least five times higher than that for the blockade of the diazepam effect."( The beta-carboline ZK 93423 inhibits reticulata neurons: an effect reversed by benzodiazepine antagonists.
Biggio, G; Carcangiu, P; Corda, MG; Giorgi, O; Mereu, G, 1987
)
0.27
" Although there was no clear-cut dose-response relationship, the results suggested a predominance of benzodiazepine-like effects at the higher dose on physiological measures whilst the lower dose was observed to have greater effects on a number of behavioural and subjective dimensions."( The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects.
Fonagy, P; Higgitt, A; Lader, M, 1986
)
0.27
"CGS-8216, a benzodiazepine antagonist, was administered to rats acutely dosed with diazepam, and to rats chronically dosed with diazepam or pentobarbital."( Benzodiazepine antagonist, CGS-8216, in diazepam- or pentobarbital-dependent and non-dependent rats.
Martin, WR; McNicholas, LF, 1986
)
0.27
" When the diazepam and zolpidem dose-response curves were re-established in the presence of a dose of Ro 15-1788 or CGS 8216 the depressant effects of the higher doses were antagonised."( Investigation of the actions of the benzodiazepine antagonists Ro 15-1788 and CGS 8216 using the schedule-controlled behavior of rats.
Sanger, DJ, 1986
)
0.27
" In different groups of rats trained to discriminate nicotine or midazolam separately from saline, neither drug appreciably altered the dose-response curve for the other, suggesting a minimal role for pharmacological interactions when effects of mixtures were assessed."( Discriminative stimulus effects of a nicotine-midazolam mixture in rats.
Norris, EA; Rauch, RJ; Stolerman, IP, 1987
)
0.27
" Flumazenil caused dose-related increases in the NPAS scores of both diazepam- and nordiazepam-dependent dogs; the slopes of the two dose-response lines were not different."( Precipitation of abstinence in nordiazepam- and diazepam-dependent dogs.
Martin, WR; McNicholas, LF; Sloan, JW; Wala, E, 1988
)
1.19
" In reproductive toxicity studies, flumazenil revealed no drug-related embryotoxic or teratogenic effect and no adverse effects upon fertility of dosed animals themselves or on the peri- and postnatal development of their offspring."( Toxicological investigations with the benzodiazepine antagonist flumazenil.
Bonetti, EP; Bürgin, H; Schläppi, B; Strobel, R, 1988
)
0.79
"" Midazolam caused a shift to the left of the GABA log dose-response curve."( Modulation of GABA-gated chloride ion flux in rat brain by acute and chronic benzodiazepine administration.
Chiu, TH; Rosenberg, HC; Yu, O, 1988
)
0.27
"Physical dependence was rapidly induced in mice by administering diazepam intraperitoneally twice daily using an incremental dosing regimen (50 to 450 mg/kg) for nine consecutive days."( A simple and rapid method of inducing physical dependence with benzodiazepines in mice.
Malick, JB; Patel, JB; Rinarelli, CA, 1988
)
0.27
" The Before Group was affected, and although complete tolerance to work-rate decrements developed rapidly to chronic dosing (3."( Midazolam and discriminative motor control: chronic administration, withdrawal and modulation by the antagonist Ro 15-1788.
Falk, JL; Lau, CE; Tang, M, 1988
)
0.27
" Oral dosing is a more efficient way of administering flumazenil than gastric fistula dosing."( Flumazenil oral absorption in dogs.
Martin, WR; McNicholas, LF; Sloan, JW; Wala, E, 1988
)
1.97
") antagonized the effects of beta-CCE, producing a shift to the right in the dose-response curves."( Interactions between the benzodiazepine receptor antagonist Ro 15-1788 (flumazepil) and the inverse agonist beta-CCE: behavioral studies with squirrel monkeys.
Barrett, JE; Brady, LS; Cook, JM; Larscheid, P; Witkin, JM, 1985
)
0.27
", failed to produce any relevant shift of the isoniazid dose-response curves to the left (proconvulsant) or to the right (anticonvulsant)."( Isoniazid-induced convulsions in rats: effects of Ro 15-1788 and beta-CCE.
Biry, P; Pieri, L, 1985
)
0.27
" Diazepam shifted GABA dose-response curves to the left by decreasing the apparent KD but without altering the apparent Vmax (Lineweaver-Burk analysis)."( Benzodiazepine receptor ligand actions on GABA responses. Benzodiazepines, CL 218872, zopiclone.
Macdonald, RL; Skerritt, JH, 1984
)
0.27
" Ro 15-1788 antagonized the depressant effect of diazepam and shifted the dose-response curve of diazepam to the right in a parallel manner but could not reverse the depression produced by either phenobarbital or chlorpromazine."( An imidazodiazepine derivative, Ro 15-1788, behaves as a weak partial agonist in the crossed extensor reflex.
Kawasaki, K; Kodama, M; Matsushita, A, 1984
)
0.27
" On acute administration FG 7142 (at doses between 10 and 40 mg kg-1) lowered seizure thresholds to infused pentylenetetrazol (PTZ) but showed an unusual dose-response curve in that higher doses had less effect."( Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling.
Little, HJ; Nutt, DJ; Taylor, SC, 1984
)
0.27
"After 3 days of dosing rats with lorazepam (0."( Recovery from lorazepam tolerance and the effects of a benzodiazepine antagonist (RO 15-1788) on the development of tolerance.
File, SE, 1982
)
0.26
" Diazepam failed to further modify the dose-response curve to adenosine obtained in the presence of dipyridamole, and uptake inhibitor."( Mechanism of potentiation by diazepam of adenosine response.
Kulkarni, SK; Mehta, AK, 1984
)
0.27
" Pretreatment with the convulsant bemegride antagonized the pentobarbital transfer but not the chlordiazepoxide cue, whereas the specific benzodiazepine antagonist RO15-1788 decreased the chlordiazepoxide cue in a dose-response manner without attenuating the pentobarbital transfer."( Specific antagonism of the behavioral effects of chlordiazepoxide and pentobarbital in the rat.
Schechter, MD, 1984
)
0.27
" 2 The central effects of orally administered diazepam (40 mg) were most pronounced 1 h after dosing and persisted for 9 h with decreasing severity."( RO 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability.
Brick, I; Darragh, A; Kenny, M; Lambe, R; O'Boyle, C; Taaffe, W, 1982
)
0.26
"Sex differences, and the influence of drug dosage and additional upper airway obstruction were studied in midazolam-induced breathing patterns and sedation in 30 healthy volunteers (8 males and 22 females)."( Differences in midazolam-induced breathing patterns in healthy volunteers.
Haji, A; Ito, Y; Masuda, A; Shakunaga, K; Shibuya, N; Wakasugi, M, 1995
)
0.29
" Prudent drug product selection, careful titration of drug dosage to ensure use of the lowest effective dose (Table 1), and vigilant monitoring of medicated patients will optimize the value of conscious sedation in colonoscopy."( Drugs and sedation for colonoscopy.
Phillips, MS, 1995
)
0.29
"01) compared to vehicle level resulted in a shallow dose-response curve across the dose range tested (0."( Nitrous oxide induces feeding in the nondeprived rat that is antagonized by naltrexone.
Czech, DA, 1995
)
0.29
" Dose-response curve for flumazenil (2."( Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat.
Korkmaz, S; Ljungblad, E; Wahlström, G, 1995
)
0.92
" The drug produced a bell-shaped dose-response profile in the alpha 1 beta 2 gamma 2 receptor subtype as monitored with GABA-induced Cl- currents in the whole cell patch-clamp technique."( Characterization of U-97775 as a GABAA receptor ligand of dual functionality in cloned rat GABAA receptor subtypes.
Carter, DB; Hamilton, BJ; Im, HK; Im, WB; Jacobsen, EJ; Pregenzer, JF, 1995
)
0.29
" In the first, dose-response experiments (n = 59) demonstrated a dose-dependent suppression of the noxiously evoked activity of spinal WDR neurons after midazolam administration."( Intravenous midazolam suppresses noxiously evoked activity of spinal wide dynamic range neurons in cats.
Hanaoka, K; Ide, Y; Nagase, M; Sekiyama, H; Sumida, T; Tagami, M, 1995
)
0.29
" These results indicate that distinct and contrasting dose-response profiles exist for these classical and atypical drugs in an animal model of anxiety based on electric shock."( Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.
Dooley, DJ; Klamt, I, 1993
)
0.29
" Repeated treatment with diazepam produced tolerance to its anticonvulsant activities as indicated by shifts of the dose-response curves by a factor of 3-5."( Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence.
Morel, E; Perrault, G; Sanger, DJ; Zivkovic, B, 1993
)
0.29
" Alzet 2001 osmotic pumps deliver at a constant rate (1 microliter/h) and dosage can be easily adjusted."( A system for testing the development and reversal of anticonvulsant tolerance to benzodiazepines in mice.
Kapetanovic, IM; Kupferberg, HJ; Torchin, CD, 1993
)
0.29
" The dose-response profile of U-94863 in the alpha 1 beta 2 subtype was largely indistinguishable from that in the alpha 1 beta 2 gamma 2 subtype, suggesting no critical role for the gamma 2 subunit in potentiation of the GABA response by the pyrazinones."( Substituted pyrazinones, a new class of allosteric modulators for gamma-aminobutyric acidA receptors.
Carter, DB; Gammill, RB; Hamilton, BJ; Im, HK; Im, WB; Judge, TM; Pregenzer, JF, 1993
)
0.29
" The dose-response curve for GABA in the presence of 10(-3) M PC-G was shifted rightward and there was a decrease in maximum response."( Effect of penicillin on GABA-gated chloride ion influx.
Ito, M; Kishi, K; Mori, C; Shiraishi, H; Tsuda, A; Tsuda, H, 1994
)
0.29
" Flumazenil and placebo groups of 12 patients each were similar with respect to age, body weight, dosage of anaesthetic drugs and surgery times."( Flumazenil facilitates intraoperative arousal during scoliosis surgery: a randomized, double-blind, placebo-controlled study.
Koscielniak-Nielsen, ZJ; Pedersen, HL; Perko, G; Schierbeck, J, 1994
)
2.64
" In new rats, a dose-response assessment revealed that 60 and 30 nmol, but not 10 nmol, CDP infused into the medial septum impaired spatial learning, but not cue learning or swim speed."( Effects of intracranial infusions of chlordiazepoxide on spatial learning in the Morris water maze. II. Neuropharmacological specificity.
McNamara, RK; Skelton, RW, 1993
)
0.29
" Thirty-two subjects completed this randomized, double-blind, placebo-controlled study investigating the dose-response relationship and duration of flumazenil's effects on ventilatory depression and hypnosis induced by a continuous midazolam infusion."( The effects of large-dose flumazenil on midazolam-induced ventilatory depression.
Flögel, CM; Ritter, JW; Wada, DR; Ward, DS, 1993
)
0.79
" Compared to behavior of vehicle-pretreated, room air-exposed rats, rat pairs exposed to nitrous oxide showed a generally inverted U-shaped dose-response curve with the maximum increase in social interaction encounters occurring at 25% and significant increase in time of active social interaction at 15-35%; higher concentrations produced a sedative effect that reduced social interaction."( Benzodiazepine receptor-mediated behavioral effects of nitrous oxide in the rat social interaction test.
Curtis, BA; Czech, DA; Hodges, BL; Maillefer, RH; Quock, RM; Wetzel, PJ, 1993
)
0.29
" Cumulative dose-response curves for chlordiazepoxide were obtained before and during chronic chlordiazepoxide administration and during chronic saline administration."( Tolerance to the behavioral effects of chlordiazepoxide: pharmacological and biochemical selectivity.
Alastra, AJ; Cohen, C; Goldberg, SR; Marley, RJ; Sannerud, CA; Serdikoff, SL, 1993
)
0.29
"Physical dependence was produced in the rat by exposure to continuous release of diazepam from silastic capsule implants (recrystallized diazepam) or by dosing through a gastric fistula."( Precipitated abstinence in the diazepam-dependent rat.
Martin, WR; Sloan, JW; Wala, EP, 1993
)
0.29
" Hepatic dysfunction results in a substantial change in the pharmacokinetic profile of flumazenil; therefore, dosage adjustment may be necessary in patients with hepatic dysfunction or in those receiving medications that alter flumazenil metabolism."( Flumazenil: a benzodiazepine antagonist.
Hoffman, EJ; Warren, EW, 1993
)
1.95
"0 mg/kg) resulted in a dose-related parallel shift to the right in the dose-response function for PB-appropriate responding in all monkeys for all three BZs."( Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline.
Nader, MA; Woolverton, WL, 1995
)
0.53
" Concomitant treatment with aniracetam (50 nmol/mouse) shifted to the right the dose-response curves and significantly increased the ED50 values for GYKI 52466, 2,3-BZ-2 and 2,3-BZ-2M."( GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice.
Chapman, AG; Chimirri, A; De Sarro, A; de Sarro, G; Gitto, R; Giusti, P; Grasso, S, 1995
)
0.29
" In the first study, 30 birds were randomly assigned to receive midazolam at a dosage of 2, 4, or 6 mg/kg of body weight (10 birds/dosage)."( Evaluation of sedation in quail induced by use of midazolam and reversed by use of flumazenil.
Day, TK; Roge, CK, 1996
)
0.52
" The dosage of cation exchange resins was decreased, oral fluids were tolerated, and the patient's general condition improved."( Effect of hydrochlorothiazide in pseudohypoaldosteronism with hypercalciuria and severe hyperkalemia.
Rosa, FC; Stone, RC; Vale, P, 1996
)
0.29
" Third, tolerance developed to the response-suppressant effects of CDP under the RI 80-s schedule, as indicated by a sixfold shift to the right in the dose-response curves for rats treated chronically with CDP when compared to saline-treated controls."( Differential tolerance to the effects of chlordiazepoxide on unpunished and punished operant responding following chronic treatment.
Lucki, I; Shumsky, JS, 1996
)
0.29
" FLU evoked dose-related tonic-clonic and clonic convulsions (five out of six rats), whereas PK (10 mg/kg) induced convulsions in only one rat (out of five); tachypnea tended to increase with the dose of both FLU and PK; twitches and jerks, backing and writhing had a significant regression on the dose of FLU; rearing tended to decrease with the dose of PK whereas FLU-evoked head bobbing and PK-evoked twitches and jerks had inverse U-shaped dose-response curves."( Comparison of abstinence syndromes precipitated by flumazenil and PK 11195 in female diazepam-dependent rats.
Jing, X; Sloan, JW; Wala, EP, 1997
)
0.55
"Diazepam in a dosage of 11."( Midazolam versus diazepam in lipid emulsion as conscious sedation for colonoscopy with or without reversal of sedation with flumazenil.
Gevers, AM; Hendrickx, A; Macken, E; Rutgeerts, P, 1998
)
0.51
" Observation sessions were conducted 1 hr after dosing on days 1, 10, 12 and 14 of each dose condition and after termination of drug dosing."( Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons.
Ator, NA; Grech, DM; Griffiths, RR; Weerts, EM, 1998
)
0.3
" A few subjects taking higher chronic benzodiazepine dosages experienced breakthrough anxiety or withdrawal symptoms, which were well managed by dosing flumazenil immediately before the anesthetic agent and by immediate posttreatment benzodiazepine administration."( The use of flumazenil in the anxious and benzodiazepine-dependent ECT patient.
Krystal, AD; Lindahl, V; Moore, S; Steffens, DC; Watts, BV; Weiner, RD, 1998
)
0.89
" Both infuse and wax ethanolic fraction at the dosage 150 mg/kg, vo, increased the number and the percentage of open arm entries of rats and mice."( Anxiolytic effect of Rubus brasilensis in rats and mice.
Haraguchi, M; Nogueira, E; Rosa, GJ; Vassilieff, VS, 1998
)
0.3
" The baseline characteristics of the patients who received flumazenil were not significantly different from those who did not receive flumazenil, with the exception of a higher mean dosage of midazolam administered to the flumazenil group."( The role of flumazenil in outpatient transesophageal echocardiography.
Bailey, KR; Martin, ML; Seward, JB; Tsang, TS, 1999
)
0.93
"These studies were undertaken to 1) determine whether repeated dosing with the peripheral benzodiazepine antagonist PK 11195 alters its ability to precipitate withdrawal abstinence in diazepam-dependent rats; 2) whether the administration of PK 11195 and the central benzodiazepine antagonist, flumazenil, 3 days apart to the same rat produces an ordering effect in the intensity of withdrawal abstinence; 3) whether there are gender differences in these effects."( The pharmacodynamics of PK 11195 in diazepam-dependent male and female rats.
Holtman, JR; Jing, X; Sloan, JW; Wala, EP, 2000
)
0.48
", necessity of an anxiogenic baseline, drug and receptor specificity, as well as the dose-response nature of the interaction, were discussed."( The inability of CCK to block (or CCK antagonists to substitute for) the stimulus effects of chlordiazepoxide.
Fox, MA; Levine, ES; Riley, AL,
)
0.13
" The oral route is optimized by dosing every hour until stool evacuation appears."( Hepatic Encephalopathy.
Blei, AT; Córdoba, J, 2001
)
0.31
" Usually, the slope of the dose-response lines for RWJ-51204 was more shallow than the full agonist anxiolytics but steeper than partial agonists in efficacy tests but typically shallow in tests for central nervous system side effects."( 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic.
Carter, AR; Cheo-Isaacs, CT; Crooke, JJ; DeLuca, S; DeVine, A; Dubinsky, B; Hochman, C; Jordan, AD; Reitz, AB; Rosenthal, DI; Shank, RP; Vaidya, AH, 2002
)
0.31
" Plasma midazolam concentrations were obtained before dosing and at 5, 30, 60, 120, 240, 300, and 360 minutes after dosing and were assayed by liquid chromatography-tandem mass spectrometry."( Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.
Bertino, JS; Jones, CL; Morrison, AL; Nafziger, AN; Rocci, ML; Rogers, JF, 2002
)
1.76
" Group B patients (20) were treated by tapering of oxazepam dosage (from 120 mg) and with saline solution (as placebo) instead of FLU for 8 days."( Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study.
Brewer, C; Gerra, G; Giusti, F; Moi, G; Zaimovic, A, 2002
)
0.69
" 6-Methylflavone (60 microM) did not significantly affect the GABA dose-response curve at rho1 GABAC receptors."( Flumazenil-independent positive modulation of gamma-aminobutyric acid action by 6-methylflavone at human recombinant alpha1beta2gamma2L and alpha1beta2 GABAA receptors.
Chebib, M; Hall, BJ; Hanrahan, JR; Johnston, GA, 2004
)
1.77
" Prolonged oral administration with twice-daily dosing of ELB 138 with either 5 or 40 mg/kg over a 5-week period was not associated with loss of anticonvulsant efficacy in the PTZ dog model."( Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures.
Löscher, W; Potschka, H; Rieck, S; Rundfeldt, C; Tipold, A, 2004
)
0.32
" Baclofen shifted the flumazenil dose-response curve to the right and down, possibly involving perceptual masking of the discriminative stimulus effects of flumazenil by agonist activity at GABAB receptors."( Discriminative stimulus effects of flumazenil: perceptual masking by baclofen, and lack of substitution with gamma-hydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone.
Carter, LP; Coop, A; France, CP; Koek, W; Wu, H, 2006
)
0.93
" GBL dosing was initiated at 100 mg/kg/day and then progressively increased stepwise by increments of 100 mg/kg to a final dose of 600 mg/kg."( Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.
Brown, PR; Froestl, W; Gibson, KM; Goodwin, AK; Griffiths, RR; Jakobs, C; Weerts, EM, 2006
)
0.33
" Signs of physical dependence were also demonstrated when chronic GBL dosing was discontinued."( Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.
Brown, PR; Froestl, W; Gibson, KM; Goodwin, AK; Griffiths, RR; Jakobs, C; Weerts, EM, 2006
)
0.33
"These data indicate that, like GHB, chronic GBL dosing produced physical dependence that likely involved the GABA-B receptor."( Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.
Brown, PR; Froestl, W; Gibson, KM; Goodwin, AK; Griffiths, RR; Jakobs, C; Weerts, EM, 2006
)
0.33
" In addition, as a bridging study, lorazepam occupancy was measured using [(3)H]flumazenil in vivo binding in rats anesthetized and dosed under micro-PET conditions."( Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] occupancy of rat brain gamma-aminobutyric acid(A) receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a]
Aigbirhio, FI; Atack, JR; Baron, JC; Beech, JS; Clark, JC; Cleij, MC; Fryer, TD; Hargreaves, RJ; Hughes, JL; Scott-Stevens, P, 2007
)
0.76
" All fenamates tested (1-100 microM) dose-dependently potentiated GABA-evoked currents; mefenamic acid (MFA) was the most potent and efficacious and was found to shift the GABA dose-response curve to the left without effect on the maximum amplitude or the GABA Hill Slope."( Characterization of the interaction between fenamates and hippocampal neuron GABA(A) receptors.
Coyne, L; Halliwell, RF; Patten, D; Su, J,
)
0.13
" The addition of flumazenil showed no significant difference to atipamezole alone, but subcutaneous administration of atipamezole alone was not sufficient in the dosage used to show an advantage compared to non-reversed cats."( Partial antagonization of midazolam-medetomidine-ketamine in cats--atipamezole versus combined atipamezole and flumazenil.
Baumgartner, C; Ebner, J; Erhardt, W; Henke, J; Wehr, U, 2007
)
0.89
"5 mg/kg) at a dose of 375 mg/kg and exhibited a U-shaped dose-response curve."( Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system.
Butterweck, V; Grundmann, O; McGregor, GP; Wang, J, 2008
)
0.35
"Incremental sublingual (SL) dosing of triazolam has emerged as a popular sedation technique."( Flumazenil reversal of sublingual triazolam: a randomized controlled clinical trial.
Heima, M; Hosaka, K; Jackson, D; Milgrom, P; Pickrell, JE, 2009
)
1.8
"Deep sedation from incremental SL dosing of triazolam is incompletely reversed by a single intraoral injection of flumazenil."( Flumazenil reversal of sublingual triazolam: a randomized controlled clinical trial.
Heima, M; Hosaka, K; Jackson, D; Milgrom, P; Pickrell, JE, 2009
)
2.01
"In awake rats, occupancy was measured at various times after oral dosing with alpha5IA (0."( The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.
Atack, JR; Burns, HD; Dawson, GR; Eng, WS; Francis, B; Gibson, RE; Hargreaves, RJ; Ryan, C; Sohal, B, 2009
)
0.35
", 5-min pretreatment) shifted the ethanol, PB, and midazolam dose-response functions rightward in a vast majority of monkeys tested (15/15, 16/17, and 11/12, respectively)."( Antagonism of the ethanol-like discriminative stimulus effects of ethanol, pentobarbital, and midazolam in cynomolgus monkeys reveals involvement of specific GABA(A) receptor subtypes.
Grant, KA; Helms, CM; Rogers, LS, 2009
)
0.35
" The limitations in their use both as choice of therapy and with respect to conservative dosage and duration of use are highlighted."( Benzodiazepines revisited--will we ever learn?
Lader, M, 2011
)
0.37
"The data suggest that the anxiolytic-like activity observed in the light/dark box procedure after acute (5 mg/kg) or 14-day repeated (1 mg/kg/day) dosing was mediated by the serotonergic system (5-HT(1A) receptors)."( Citrus aurantium L. essential oil exhibits anxiolytic-like activity mediated by 5-HT(1A)-receptors and reduces cholesterol after repeated oral treatment.
Cassettari, BO; Costa, CA; Costa, M; Cury, TC; Flório, JC; Takahira, RK, 2013
)
0.39
"Pharmacogenetic based dosing recommendations are provided in FDA-approved warfarin label for Caucasians."( Interethnic variability of CYP4F2 (V433M) in admixed population of Roma and Hungarians.
Ganczer, A; Janicsek, I; Matyas, P; Melegh, B; Melegh, BI; Sipeky, C; Szabo, I; Szalai, R; Tarlos, G; Varnai, R; Weber, A, 2015
)
0.42
" Considering the long half-life of diazepam and its metabolites, concomitant use of theophylline may reduce the need for repeated dosing of flumazenil in patients with acute diazepam poisoning."( Determination of flumazenil in serum by liquid chromatography-mass spectrometry: Application to kinetics study in acute diazepam overdose.
Djordjević, S; Jović-Stosić, J; Kilibarda, V; Perković-Vukcević, N; Segrt, Z, 2016
)
0.98
"12mg/kg/infusion) were tested, producing an inverted U-shaped dose-response curve."( The differential effects of alprazolam and oxazepam on methamphetamine self-administration in rats.
Goeders, NE; Guerin, GF; Spence, AL, 2016
)
0.43
"Oxazepam significantly reduced methamphetamine self-administration as demonstrated by a downward shift of the dose-response curve."( The differential effects of alprazolam and oxazepam on methamphetamine self-administration in rats.
Goeders, NE; Guerin, GF; Spence, AL, 2016
)
0.43
" Additional studies are recommended that examine the anxiolytic and antidepressant effects of curcumin through alternate dosing regimens, modulation of other subunits on the GABAA receptor, and interactions with other central nervous system neurotransmitter systems."( Investigation of the Anxiolytic and Antidepressant Effects of Curcumin, a Compound From Turmeric (Curcuma longa), in the Adult Male Sprague-Dawley Rat.
Ceremuga, TE; Golder, J; Helmrick, K; Keller, B; Kelley, J; Kufahl, Z; Padrón, G; Philippe, F,
)
0.13
"The present work aims to investigate the anxiolytic activity of 6-styryl-2-pyrone (STY), obtained from Aniba panurensis, in behavioral tests and amino acids dosage on male Swiss mice."( The anxiolytic-like effect of 6-styryl-2-pyrone in mice involves GABAergic mechanism of action.
Barbosa-Filho, JM; Chaves, EMC; Dantas, LP; Honório-Júnior, JER; Lúcio, ASSC; Monteiro, VS; Nonato, DTT; Patrocínio, MCA; Sousa, CNS; Vasconcelos, SMM; Viana, GSB, 2018
)
0.48
" A battery of psychomotor tests was administered before dosing and several times postdose over 4-6 h."( Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote.
Chen, X; Hu, P; Huang, Y; Jiang, J; Sang, N; Song, K; Wang, H; Zhong, W, 2020
)
0.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
GABA antagonistA compound that inhibits the action of gamma-aminobutyric acid.
antidote to benzodiazepine poisoningA role borne by a molecule that acts to counteract or neutralise the deleterious effects of benzodiazepines.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
imidazobenzodiazepineAny organic heterotricyclic compound that is any benzodiazepine which is ortho-fused with a imidazole.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (76)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00500.003245.467312,589.2998AID2517
endonuclease IVEscherichia coliPotency10.00000.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.13370.100020.879379.4328AID488772; AID588456
phosphopantetheinyl transferaseBacillus subtilisPotency100.00000.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency4.10950.000811.382244.6684AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.03160.001318.074339.8107AID926
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.60320.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency21.97460.000417.946075.1148AID1346784; AID1347036
regulator of G-protein signaling 4Homo sapiens (human)Potency0.00600.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency18.34580.001310.157742.8575AID1259255; AID1259256
GVesicular stomatitis virusPotency13.45040.01238.964839.8107AID1645842
arylsulfatase AHomo sapiens (human)Potency0.09531.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00080.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency10.00000.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency1.58490.00255.840031.6228AID899
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency4.68370.00419.984825.9290AID504444; AID720524
flap endonuclease 1Homo sapiens (human)Potency29.93490.133725.412989.1251AID588795
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.10000.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency0.32640.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency1.25890.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency0.11220.00419.962528.1838AID2675
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency2.81840.00106.000935.4813AID944
Interferon betaHomo sapiens (human)Potency13.45040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)Ki0.00090.00090.89545.6234AID239299; AID41860
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki0.02550.00020.656110.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)Ki0.00090.00090.89545.6234AID239299; AID41860
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)420.30000.11007.190310.0000AID1209455; AID1443980; AID1443986; AID1449628; AID1473738
Gamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)IC50 (µMol)0.00050.00050.53857.2000AID41862
Gamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)Ki0.00080.00010.04380.1630AID262962; AID41853; AID41860; AID41870; AID41872
Gamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)IC50 (µMol)0.00050.00050.53857.2000AID41862
Gamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)Ki0.00080.00010.04380.1630AID262962; AID41853; AID41860; AID41870; AID41872
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki0.00090.00000.12345.5000AID239299
Gamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)IC50 (µMol)0.00050.00050.53857.2000AID41862
Gamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)Ki0.00080.00010.04530.1630AID262962; AID41853; AID41860; AID41870; AID41872
Gamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)IC50 (µMol)0.00050.00050.53857.2000AID41862
Gamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)Ki0.00080.00010.04530.1630AID262962; AID41853; AID41860; AID41870; AID41872
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Ki0.00090.00000.10825.5000AID239299
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)Ki0.00490.00000.21085.6234AID1777983; AID1798656; AID219794; AID239299; AID345418; AID41860; AID72927
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki0.02550.00020.656110.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)Ki0.00090.00090.83985.6234AID239299; AID41860
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki0.02550.00020.656110.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)Ki0.01170.00000.18819.0000AID1798656; AID219794; AID219940; AID219954; AID239299; AID345419; AID345620; AID41860; AID71266; AID71268; AID72927; AID73089; AID73244; AID73523; AID73530
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.505710.0000AID40239
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki0.03050.00020.561410.0000AID219782; AID219783; AID219947; AID220441; AID220443; AID220445; AID220446; AID220448; AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.00080.00010.739610.0000AID40377
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.497310.0000AID40239
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki0.02550.00020.635210.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.02240.00020.621710.0000AID219947; AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)IC50 (µMol)0.00050.00050.53857.2000AID41862
Gamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)Ki0.00080.00010.04530.1630AID262962; AID41853; AID41860; AID41870; AID41872
Gamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)IC50 (µMol)0.00050.00050.53857.2000AID41862
Gamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)Ki0.00080.00010.04530.1630AID262962; AID41853; AID41860; AID41870; AID41872
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.498810.0000AID40239
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki0.02550.00020.675810.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.504610.0000AID40239
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.02550.00020.646910.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki0.02550.00020.656110.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)Ki0.02540.00010.20769.0000AID219794; AID219940; AID219954; AID239299; AID41860; AID71266; AID71268; AID72927; AID73089; AID73244; AID73523; AID73530
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki0.02550.00020.656110.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki0.02920.00020.671210.0000AID220441; AID220443; AID220445; AID220446; AID220448; AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)Ki0.00490.00010.24425.6234AID1777982; AID1798656; AID239299; AID41860; AID73523; AID73530
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)Ki0.00500.00010.25155.6234AID1777985; AID1798656; AID219954; AID239299; AID345620; AID41860; AID73244
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)Ki0.00490.00010.24015.6234AID1777984; AID1798656; AID219940; AID239299; AID345419; AID41860; AID73089
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)Ki0.00550.00000.28325.6234AID1798656; AID239299; AID345419; AID345620; AID41860
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)Ki0.00520.00020.37095.6234AID1798656; AID239299; AID345421; AID41860
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.506510.0000AID40239
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki0.03170.00020.557710.0000AID219782; AID219783; AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.505710.0000AID40239
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki0.02550.00020.640310.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki0.03050.00020.570810.0000AID219782; AID219783; AID219947; AID220441; AID220443; AID220445; AID220446; AID220448; AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)Ki0.00090.00090.89545.6234AID239299; AID41860
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)Ki0.09000.00000.73078.0000AID220441
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)Ki0.01950.00020.41199.0000AID1777986; AID1798656; AID239299; AID41860; AID71266; AID71268
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)Ki0.00090.00090.89545.6234AID239299; AID41860
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
GABA theta subunitRattus norvegicus (Norway rat)Ki0.02550.00020.656110.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)Ki0.00090.00090.89545.6234AID239299; AID41860
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)0.00380.00010.507510.0000AID40239
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki0.02550.00020.656110.0000AID40376; AID40377; AID40380; AID40381; AID40670; AID40970; AID72132
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)Ki0.00090.00090.89545.6234AID239299; AID41860
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)Kd0.00200.00010.01020.0760AID343089
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)Kd0.00040.00040.00040.0004AID726250
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)Kd0.00040.00040.00040.0004AID726250
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)Kd0.00050.00050.12830.8260AID343090
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)Kd0.00040.00040.00040.0004AID726250
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (129)

Processvia Protein(s)Taxonomy
chloride transmembrane transportGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to toxic substanceGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
central nervous system neuron developmentGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to progesteroneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ovulation cycleGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
negative regulation of chloride transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
response to xenobiotic stimulusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neurotransmitter transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (63)

Processvia Protein(s)Taxonomy
GABA-A receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane signaling receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter transmembrane transporter activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (64)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
apical plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
axonGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Bos taurus (cattle)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Bos taurus (cattle)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
nuclear envelopeGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
presynaptic active zone membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleolusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
microtubule cytoskeletonGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (333)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1798656Radioligand Binding Assay from Article 10.1021/jm800889m: \\Structural Requirements for Eszopiclone and Zolpidem Binding to the gamma-Aminobutyric Acid Type-A (GABAA) Receptor Are Different.\\2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40525Agonistic activity against specific binding of radioligand [3H]Ro-151788 to GABA-A Benzodiazepine receptor in rat cortex1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Structure-activity relationship studies at the benzodiazepine receptor (BZR): a comparison of the substitutent effects of pyrazoloquinolinone analogs.
AID229555Relative binding to GABA-A receptor in the presence and absence of GABA1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Structure-activity relationship studies at the benzodiazepine receptor (BZR): a comparison of the substitutent effects of pyrazoloquinolinone analogs.
AID345469Ratio of Ki for GABAA alpha1 T206C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID233756GABA ratio, relative binding in the presence and absence of 10 uM GABA (IC50-GABA/IC50+GABA)2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID365609Displacement of [3H]flumazenil from CBR in human cortical membrane2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
AID113815Anticonvulsant activity against convulsions induced by DMCM1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABAA receptors.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26380Dissociation constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID359228Activity at rat wild type GABAA alpha-1V202Cbeta-2-gamma-2 mutant receptor expressed in xenopus oocytes assessed as GABA-elicited response by two electrode voltage clamp method relative to control2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Proximity-accelerated chemical coupling reaction in the benzodiazepine-binding site of gamma-aminobutyric acid type A receptors: superposition of different allosteric modulators.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID345449Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 D56C receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID345459Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 R185C receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID72133Binding affinity against Diazepam sensitive (DS) Gamma-aminobutyric acid A receptor in rat cerebellum.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis of novel imidazobenzodiazepines as probes of the pharmacophore for "diazepam-insensitive" GABAA receptors.
AID345456Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 T142C receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID1301529Displacement of [3H]-flumazenil from central-type benzodiazepine receptor in bovine cortical membrane after 90 mins by liquid-phase scintillation beta-counting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID345428Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 T126C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID220296Binding affinity for rat GABA-A receptor alpha-5--beta-2-gamma-2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID40376Binding affinity for Diazepam insensitive (DI) isoform of the benzodiazepine (Bz) binding site on GABAA receptors1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID419300Effect on learning and memory process in CD1 albino mouse assessed as improvement in retention latency at 100 mg/kg, ip after 24 hrs by passive avoidance test2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.
AID222342Anxiolytic activity in mice using light-dark box and % time spent in light was reported at 30 mg/kg intraperitoneal dose2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID219794Binding affinity against alpha-1-beta-3-gamma-2 GABAA/BzR receptor subtype.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID41741Inhibition of [35S]-TBPS binding to GABA-A central Benzodiazepine Receptor of bovine cerebral cortex membranes2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.
AID345432Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 T142C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID345422Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-5-beta-2-gamma-2 receptor expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID701021Displacement of [3H]flumazenil from central benzodiazepine receptor in bovine cortical membrane after 90 mins by beta liquid scintillation counting2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID345439Displacement of [3H]Ro15-1788 from benzodiazepine binding site of GABAA alpha-1 G157C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID226428Ratio of Ki value without GABA and Ki value in the presence of GABA.1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABA(A) receptor complex.
AID359880Activity at rat wild type GABAA alpha-1-beta-2-gamma-2 receptor expressed in xenopus oocytes assessed as GABA-elicited response by two electrode voltage clamp method relative to control2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Proximity-accelerated chemical coupling reaction in the benzodiazepine-binding site of gamma-aminobutyric acid type A receptors: superposition of different allosteric modulators.
AID220443Binding affinity for mutant rat GABA-A receptor alpha-6-(his)-beta-2-gamma-2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID345429Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 M130C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID71572Inhibition of TBPS binding to GABA-A receptor of bovine brain membranes at 0.5 uM relative to clonazepam1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID234197Selectivity for Diazepam insensitive compared to sensitive GABA-A benzodiazepine receptor fractions1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepine receptors.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID343090Binding affinity to GABAA alpha-5-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID345461Ratio of Ki for GABAA alpha1 F99C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID110242Anticonvulsant activity against PTZ induced atacks1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Benzodiazepine receptor ligands. 4. Synthesis and pharmacological evaluation of 3-heteroaryl-8-chloropyrazolo[5,1-c][1,2,4] benzotriazine 5-oxides.
AID39939Displacement of [3H]flunitrazepam at GABA-A benzodiazepine receptor in rat brain cortical membranes1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand.
AID345450Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 M130C receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID345460Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 R194C receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID40239Inhibition of radiolabeled antagonist [3H]-Ro- 15-1788 binding to benzodiazepine receptor from rat cortical membranes1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Novel benzodiazepine receptor partial agonists: oxadiazolylimidazobenzodiazepines.
AID345465Ratio of Ki for GABAA alpha1 G200C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID345458Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 X161 receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID359234Activity at rat GABAA alpha-1H101Cbeta-2-gamma-2 mutant receptor expressed in xenopus oocytes assessed as change in GABA-induced current amplitude at 1 uM after 1 min exposure to GABA by two electrode voltage clamp method2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Proximity-accelerated chemical coupling reaction in the benzodiazepine-binding site of gamma-aminobutyric acid type A receptors: superposition of different allosteric modulators.
AID220446Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr,gly)beta2gamma2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID222062Dose required to antagonise the convulsant action of PTZ (80 mg/kg, sc) in 50% mice; No effect at a highest dose of 100 mg/kg2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.
AID345421Displacement of [3H]Ro-154513 from benzodiazepine binding site of GABAA alpha-4-beta-2-gamma-2 receptor expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID359229Activity at rat wild type GABAA alpha-1V211Cbeta-2-gamma-2 mutant receptor expressed in xenopus oocytes assessed as GABA-elicited response by two electrode voltage clamp method relative to control2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Proximity-accelerated chemical coupling reaction in the benzodiazepine-binding site of gamma-aminobutyric acid type A receptors: superposition of different allosteric modulators.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID345463Ratio of Ki for GABAA alpha1 A160C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID726250Binding affinity to human GABAA alpha3beta2gamma2 expressed in thymidine kinase-deficient L cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Ion channels as therapeutic targets: a drug discovery perspective.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID345435Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 R185C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID345454Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 R132C receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID359881Activity at rat wild type GABAA alpha-1H101Cbeta-2-gamma-2 mutant receptor expressed in xenopus oocytes assessed as GABA-elicited response by two electrode voltage clamp method relative to control2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Proximity-accelerated chemical coupling reaction in the benzodiazepine-binding site of gamma-aminobutyric acid type A receptors: superposition of different allosteric modulators.
AID679768TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Flumazenil: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID345452Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 T81C receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID220441Binding affinity for rat GABA-A receptor alpha-6-beta-2-gamma-2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID72591Specific [35S]- TBPS binding at high affinity site loated near chloride channel of GABA-A receptor chloride complex1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Synthesis, structure-activity relationships, and molecular modeling studies of N-(indol-3-ylglyoxylyl)benzylamine derivatives acting at the benzodiazepine receptor.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID345424Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 D56C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID345433Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 R144C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID345448Displacement of [3H]Ro15-1788 from benzodiazepine binding site of GABAA alpha-1 V211C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID1777983Binding affinity to GABBA alpha1 (unknown origin)
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID40670In vitro affinity against Benzodiazepine receptor binding to rat cortical membranes (using [3H]- flumazenil as radioligand).1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABA(A) receptor complex.
AID42310In vitro efficacy for GABA-A benzodiazepine receptor of rat brain receptor, GABA ratio is IC50(-GABA) / IC50(+ 0.1 mM GABA)1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand.
AID345442Displacement of [3H]Ro15-1788 from benzodiazepine binding site of GABAA alpha-1 G200C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID221437Antagonism of Diazepam (2.5 mg/kg, ip) anticonvulsant effect in mice treated with PTZ (80 mg/kg, sc)2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.
AID345457Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 R144C receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1777986Binding affinity to GABBA alpha6 (unknown origin)
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID345444Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha1 S204C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID345467Ratio of Ki for GABAA alpha1 S204C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID40377Binding affinity for Diazepam sensitive (DS) isoform of the benzodiazepine (Bz) binding site on GABAA receptors1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID527596Agonist activity at human recombinant GABAA alpha-5-beta-3-gamma-2 receptor expressed in Xenopus oocytes at 1 to 10 uM by patch clamp technique2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID419310Effect on learning and memory process in CD1 albino mouse assessed as training latency at 100 mg/kg, po administered 30 mins before test by passive avoidance test2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID345470Ratio of Ki for GABAA alpha1 V211C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID122709Antianxiety activity was measured based on light/dark box thus calculated no of crosses of mice1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Benzodiazepine receptor ligands. 4. Synthesis and pharmacological evaluation of 3-heteroaryl-8-chloropyrazolo[5,1-c][1,2,4] benzotriazine 5-oxides.
AID345426Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 A79C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID73089Binding affinity to human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-2-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID239299Displacement of [3H]flumazenil from bovine benzodiazepine receptor GABA-A channel of brain membranes2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
High affinity central benzodiazepine receptor ligands: synthesis and biological evaluation of a series of phenyltriazolobenzotriazindione derivatives.
AID1597724Half life in human at 1 mg2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Sleep modulating agents.
AID222221Motor coordination of mouse as number of falls in 30 sec was reported after 100 mg/kg intraperitoneal dose using rotarod test2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID226274Relative binding to GABA-A central benzodiazepine receptor in the presence and absence of 10e-4 M GABA (GABA shift)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Benzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID122849Muscle relaxant effect measured by rotarod test1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Benzodiazepine receptor ligands. 4. Synthesis and pharmacological evaluation of 3-heteroaryl-8-chloropyrazolo[5,1-c][1,2,4] benzotriazine 5-oxides.
AID222222Motor coordination of mouse as number of falls in 30 sec was reported after 30 mg/kg intraperitoneal dose using rotarod test2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID73530Binding affinity for Gamma-aminobutyric acid A receptor alpha-5-beta-3-gamma-21998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID365611Ratio of Ki for human CBR in absence of GABA to Ki for human CBR in presence of 50 uM GABA2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
AID701027Antagonist activity at central benzodiazepine receptor in Sprague-Dawley rat cerebrocortical synaptoneurosomes assessed as effect on GABA-induced [36]chloride ion flow after 10 seconds by beta liquid scintillation counting2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID345446Displacement of [3H]Ro15-1788 from benzodiazepine binding site of GABAA alpha-1 T206C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID71268Binding affinity against Gamma-aminobutyric acid A receptor alpha-6-beta-3-gamma-21998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID537227Effect on learning and memory process in CD1 albino mouse assessed as improvement in retention latency at 100 mg/kg, po after 24 hrs by passive avoidance test2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
New fluoro derivatives of the pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide system: evaluation of fluorine binding properties in the benzodiazepine site on γ-aminobutyrric acid type A (GABA(A)) receptor. Design, synthesis, biological, and molecular modeling
AID220448Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr,gly,val)beta2gamma2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID219782Binding affinity for rat GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID222066Proconvulsant action measured as the dose required to induce convulsions in 50% of mice that had been previously given a subconvulsant dose of PTZ (40 mg/kg, sc); No effect at a highest dose of 100 mg/kg2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.
AID41983Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives.
AID222351Percent anticonvulsant activity against pentylenetetrazole (PTZ)-induced attacks at 100 mg/kg intraperitoneal dose.2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID226427Ratio of IC50 of compound to that of compound+10 uM GABA1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Tricyclic heteroaromatic systems. [1]benzopyranopyrrol-4-ones and [1]benzopyrano-1,2,3-triazol-4-ones as benzodiazepine receptor ligands. Synthesis and structure-activity relationships.
AID701022Displacement of [3H]flumazenil from central benzodiazepine receptor in human cortical membrane after 90 mins by beta liquid scintillation counting2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID219795It is the ratio of Ki value for alpha-1-beta-3-gamma-2 to that of alpha-5-beta-3-gamma-21998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID345427Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 T81C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID1692393Displacement of [3H]diazepam from Benzodiazepine receptor in rat cerebral cortex membrane2020European journal of medicinal chemistry, Aug-15, Volume: 200Design, synthesis and biological evaluation of 7-substituted 4-phenyl-6H-imidazo[1,5-a]thieno[3,2-f] [1,4]diazepines as safe anxiolytic agents.
AID72138Binding affinity to rat chimeric GABA-A receptor C6, alpha1-alpha6 chimeric subunit co-expressed with beta-2 gamma2 subunits in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID1301531Selectivity ratio, ratio of Ki for central-type benzodiazepine receptor in bovine cortical membrane to Ki for central-type benzodiazepine receptor in bovine cortical membrane in presence of 50 uM of GABA2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID345423Displacement of [3H]Ro-154513 from benzodiazepine binding site of GABAA alpha-6-beta-2-gamma-2 receptor expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID41853In vitro inhibition of [3H]-Ro- 15-1788 binding to GABA-A Benzodiazepine receptor of bovine brain membranes1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors.
AID73244Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-3-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID345451Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 A79C receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID219954Binding affinity against alpha-3-beta-3-gamma-2 GABAA/BzR receptor subtype.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID345440Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha1 A160C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID222223Anxiolytic activity in mice using light-dark box and no. of transfers between compartments were reported at 100 mg/kg intraperitoneal dose2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID345437Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha1 D97C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID365610Ratio of Ki for bovine CBR in absence of GABA to Ki for bovine CBR in presence of 50 uM GABA2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID41860Binding affinity towards Benzodiazepine receptor from bovine brain membrane using [3H]Ro-151788 as radioligand2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID345430Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 R132C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID1777985Binding affinity to GABBA alpha3 (unknown origin)
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID226275Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID327589Displacement of [3H]flumazenil from GABAA/BzR complex in bovine cerebral cortex membrane2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Novel 3-aroylpyrazolo[5,1-c][1,2,4]benzotriazine 5-oxides 8-substituted, ligands at GABAA/benzodiazepine receptor complex: synthesis, pharmacological and molecular modeling studies.
AID345462Ratio of Ki for GABAA alpha1 G157C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID220130Binding affinity for mutant rat GABA-A receptor alpha-4-(his)-beta-2-gamma-2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID345620Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-3-beta-2-gamma-2 receptor expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID345425Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 F77C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID701023Ratio of Ki for central benzodiazepine receptor in bovine cortical membrane to Ki for central benzodiazepine receptor in bovine cortical membrane in presence of 50 uM GABA2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID72312Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Synthesis, structure-activity relationships, and molecular modeling studies of N-(indol-3-ylglyoxylyl)benzylamine derivatives acting at the benzodiazepine receptor.
AID220445Binding affinity for mutant rat GABA-A receptor alpha-6-(his,thr)beta2gamma2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID219947Binding affinity for rat GABA-A receptor alpha-3-beta-2-gamma-2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID365608Displacement of [3H]flumazenil from CBR in bovine cortical membrane2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent.
AID1477185Anxiolytic-like activity in Swiss albino mouse assessed as persistent time in light box at 100 mg/kg, ip administered 40 mins prior to testing by light dark box test (131.9 +/- 6.5 secs)
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1777984Binding affinity to GABBA alpha2 (unknown origin)
AID343089Binding affinity to GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
AID280839Displacement of [3H]flumazenil from benzodiazepine receptor in bovine brain membranes2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands.
AID41872Inhibition of [3H]flumazenil binding to GABA-A benzodiazepine receptor of bovine brain membranes2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular modeling analysis of the structure-activity relationships.
AID1777982Binding affinity to GABBA alpha5 (unknown origin)
AID71266Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-6-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID345468Ratio of Ki for GABAA alpha1 S205C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID701024Ratio of Ki for central benzodiazepine receptor in human cortical membrane to Ki for central benzodiazepine receptor in human cortical membrane in presence of 50 uM GABA2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds.
AID232720Selectivity ratio of alpha1 beta-3 gamma2 GABA A / BzR and alpha5 beta-3 gamma2 GABA A / BzR2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID345436Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 R194C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID345455Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 L140C receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID356507Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 0.3 mg/kg, po for 7 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID345466Ratio of Ki for GABAA alpha1 V202C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID1775019Sleep-promoting activity in ddY mouse assessed as decrease in pentobarbital-induced sleep ing duration at 3 mg/kg relative to control
AID219783Binding affinity for mutant rat GABA-A receptor alpha-1-(arg)-beta-2-gamma-2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID40380Binding affinity for Diazepam-Insensitive fraction of GABA-A benzodiazepine receptors1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepine receptors.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1632645In vivo displacement of [11C]FMZ from rhesus monkey GABA-A receptor at 0.5 mg/kg, iv after 50 to 90 mins by PET analysis2016ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8
Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET.
AID345464Ratio of Ki for GABAA alpha1 T162C beta2gamma2 receptor mutant to Ki for GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID345443Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha1 V202C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID40381Binding affinity for Diazepam-Sensitive fraction of GABA-A benzodiazepine receptors1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepine receptors.
AID345447Displacement of [3H]Ro15-1788 from benzodiazepine binding site of GABAA alpha1 Y209C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID226431Relative binding to GABA-A receptor in the presence and absence of GABA (GABA shift), Ki(-GABA)/Ki(+GABA)1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors.
AID233962Ratio of binding affinity against DI Bz receptor to that of DS Bz receptor1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors.
AID1301538Partial inverse agonist activity at central-type benzodiazepine receptor in Sprague-Dawley rat cerebrocortical synaptoneurosomes assessed as decrease in 36Cl- flow after 10 secs by liquid-phase scintillation beta-counting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID345453Ratio of Ki for GABAA alpha-1-beta-2-gamma-2 T126C receptor mutant to Ki for GABAA alpha1beta2gamma2 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID219940Binding affinity tested against alpha-2-beta-3-gamma-2 GABAA/BzR receptor subtype.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID72927Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-1-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID222341Anxiolytic activity in mice using light-dark box and % time spent in light was reported at 100 mg/kg intraperitoneal dose2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID41862Affinity to displace [3H]flunitrazepam from Benzodiazepine receptor in bovine brain membrane1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Tricyclic heteroaromatic systems. [1]benzopyranopyrrol-4-ones and [1]benzopyrano-1,2,3-triazol-4-ones as benzodiazepine receptor ligands. Synthesis and structure-activity relationships.
AID122997Antagonistic effect against the anticonvulsant Diazepam (2.5 mg/kg, ip) effect in mice after PTZ (80 mg/kg, sc) dose1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors.
AID220128Binding affinity for rat GABA-A receptor alpha-4-beta-2-gamma-2 subunits expressed in HEK293 cells1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID672795Displacement of [3H]flumazenil from central benzodiazepine receptor in rat cerebral cortex membranes at 10 uM after 90 mins by competitive binding assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein.
AID359882Activity at rat wild type GABAA alpha-1G157Cbeta-2-gamma-2 mutant receptor expressed in xenopus oocytes assessed as GABA-elicited response by two electrode voltage clamp method relative to control2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Proximity-accelerated chemical coupling reaction in the benzodiazepine-binding site of gamma-aminobutyric acid type A receptors: superposition of different allosteric modulators.
AID345445Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha1 S205C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID356506Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 0.3 mg/kg, po for 7 days measured 24 hrs after final drug administration by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID345418Displacement of [3H]Ro15-1788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 receptor expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID113288Antagonistic effect against PTZ (80 mg/kg, sc) convulsant action in mice1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors.
AID41873Ratio of Ki with out GABA and with GABA2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular modeling analysis of the structure-activity relationships.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID262962Displacement of [3H]flumazenil from GABA-A receptor in bovine brain membranes2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Refinement of the benzodiazepine receptor site topology by structure-activity relationships of new N-(heteroarylmethyl)indol-3-ylglyoxylamides.
AID113814Anticonvulsant activity against convulsions induced by Compound 91996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABAA receptors.
AID41870In vitro inhibition of [3H]flunitrazepam binding to GABA-A benzodiazepine receptor of bovine cerebral cortical membranes at 10 uM1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID592683Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID527594Agonist activity at human recombinant GABAA alpha-3-beta-3-gamma-2 receptor expressed in Xenopus oocytes at 1 to 10 uM by patch clamp technique2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse.
AID226435GABA shift ratio at Diazepam sensitive fraction of GABA-A benzodiazepine receptor1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepine receptors.
AID1301534Displacement of [3H]-flumazenil from central-type benzodiazepine receptor in human cortical membrane after 90 mins by liquid-phase scintillation beta-counting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID72132Binding affinity against Diazepam insensitive (DI) Gamma-aminobutyric acid A receptor1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Synthesis of novel imidazobenzodiazepines as probes of the pharmacophore for "diazepam-insensitive" GABAA receptors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID613587Ex vivo binding affinity to TSPO in AMPA lesioned rat assessed as increase in ipsi to contralateral ratio by auto radiography2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
AID345441Displacement of [3H]Ro15-1788 from benzodiazepine binding site of GABAA alpha1 T162C beta-2-gamma-2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID345434Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 X161 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID124453Antianxiety activity was measured based on light/dark box thus calculated % time in light of mice1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Benzodiazepine receptor ligands. 4. Synthesis and pharmacological evaluation of 3-heteroaryl-8-chloropyrazolo[5,1-c][1,2,4] benzotriazine 5-oxides.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID226437Ratio of binding affinity to the GABA-A receptor in the presence and absence of GABA1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Novel benzodiazepine receptor partial agonists: oxadiazolylimidazobenzodiazepines.
AID721184Displacement of [3F]FMZ from Wistar rat cerebellum GABAA receptor by competitive radioligand assay2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
The development of potential new fluorine-18 labelled radiotracers for imaging the GABA(A) receptor.
AID345431Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-1-beta-2-gamma-2 L140C receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID592682Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID527592Agonist activity at human recombinant GABAA alpha-1-beta-3-gamma-2 receptor expressed in Xenopus oocytes at 1 to 10 uM by patch clamp technique2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse.
AID123505Convulsant effect in mice following subconvulsant PTZ(40 mg/kg, sc) dose, ineffective to 250 mg/kg1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors.
AID73523Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-5-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID1301535Selectivity ratio, ratio of Ki for central-type benzodiazepine receptor in human cortical membrane to Ki for central-type benzodiazepine receptor in human cortical membrane in presence of 50 uM of GABA2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
AID222224Anxiolytic activity in mice using light-dark box and no. of transfers between compartments were reported at 30 mg/kg intraperitoneal dose2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID40970In vitro binding affinity against benzodiazepine receptor using [3H]diazepam as radioligand1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Benzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.
AID345438Displacement of [3H]Ro15-1788 from benzodiazepine binding site of GABAA alpha-1 F99C beta2gamma2 receptor mutant expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID721183Lipophilicity, log D of the compound in n-octanol at pH 7.4 by shake flask method2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
The development of potential new fluorine-18 labelled radiotracers for imaging the GABA(A) receptor.
AID41988Displacement of [3H]- Ro.15-1788 from GABA-A central Benzodiazepine receptor (BzR) of Bovine cerebral cortex membrane2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.
AID222352Percent anticonvulsant activity against pentylenetetrazole (PTZ)-induced attacks at 30 mg/kg intraperitoneal dose.2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
AID345419Displacement of [3H]Ro-151788 from benzodiazepine binding site of GABAA alpha-2-beta-2-gamma-2 receptor expressed in HEK293T cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346520Human GABAA receptor alpha1 subunit (GABAA receptors)1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID1346513Human GABAA receptor alpha5 subunit (GABAA receptors)1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID1346541Human GABAA receptor alpha6 subunit (GABAA receptors)1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID1346503Rat GABAA receptor alpha4 subunit (GABAA receptors)1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor.
AID1346504Human GABAA receptor alpha2 subunit (GABAA receptors)1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID1346496Human GABAA receptor alpha3 subunit (GABAA receptors)1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via compar
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID493017Wombat Data for BeliefDocking2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,428)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901006 (22.72)18.7374
1990's1481 (33.45)18.2507
2000's875 (19.76)29.6817
2010's810 (18.29)24.3611
2020's256 (5.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 88.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index88.89 (24.57)
Research Supply Index8.54 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index164.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (88.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials426 (9.12%)5.53%
Reviews288 (6.16%)6.00%
Case Studies322 (6.89%)4.05%
Observational11 (0.24%)0.25%
Other3,626 (77.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Flumazenil on Hypoactive Delirium in the ICU: A Double-Blind, Placebo-Controlled Pilot Study [NCT02899156]Phase 422 participants (Actual)Interventional2016-03-31Terminated(stopped due to A planned interim analysis led to the trial being stopped early based on the observed size effect and power analysis.)
Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm [NCT03462641]Phase 1/Phase 236 participants (Actual)Interventional2018-03-09Completed
Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination [NCT03743805]Early Phase 10 participants (Actual)Interventional2019-01-01Withdrawn(stopped due to Insufficient patients)
Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane: a Randomized Controlled Trial [NCT02157428]36 participants (Actual)Interventional2011-01-31Completed
Comparison of Remimazolam With Flumazenil vs. Propofol TIVA During RFCA for Atrial Fibrillation [NCT05397886]54 participants (Actual)Interventional2022-08-02Completed
Treatment of Hepatic Encephalopathy With Benzodiazepine Antagonist (Flumazenil) and Change in Cortical GABA Levels in Localized 1H-MR Spectroscopy [NCT02048969]Phase 1/Phase 20 participants (Actual)Interventional2014-06-30Withdrawn(stopped due to No subjects were able to be recruited for the study.)
An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325 After Oral Administration to Healthy Volunteers [NCT00681720]Phase 14 participants (Actual)Interventional2008-02-29Completed
An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 After Oral Administration to Healthy Volunteers [NCT00681746]Phase 18 participants (Anticipated)Interventional2008-02-29Completed
Flumazenil Rescue Strategy [NCT00695630]Phase 1/Phase 214 participants (Actual)Interventional2006-09-30Completed
Cross-Species Multi-Modal Neuroimaging to Investigate GABA Physiology in Fragile X Syndrome [NCT04308954]Phase 117 participants (Actual)Interventional2016-11-01Terminated(stopped due to Difficulty with patient recruitment due to COVID-19 pandemic)
A Phase 1/2,Open-Label Study to Evaluate the Safety and Efficacy of the International Brain Research Foundation (IBRF) Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Patients With Severe Disorders of Consciousness [NCT02696512]Phase 1/Phase 230 participants (Anticipated)Interventional2016-03-31Recruiting
Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence [NCT01904487]Phase 111 participants (Actual)Interventional2011-04-19Completed
Double-blind, Randomized, Placebo and Active Controlled Study to Assess the Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy Adults(Zolpidem or Brotizolam) [NCT01071889]Phase 1/Phase 210 participants (Actual)Interventional2010-05-31Completed
Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder. [NCT00997087]Phase 211 participants (Actual)Interventional2009-10-31Terminated(stopped due to Study completed and data was inconclusive.)
The Sedation Effect of Electro-acupuncture on Bilateral Zusanli (ST 36) and Neiguan (PC 6) in General Anesthesia May Not be Mediated by the Benzodiazepines- GABA Pathway [NCT02690389]80 participants (Actual)Interventional2015-01-31Completed
Contribution of Gabaergic and Glutamatergic Mechanisms to Cognitive Dysfunction [NCT00611572]Phase 123 participants (Actual)Interventional2007-01-31Completed
Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil Compared to Propofol-based Total Intravenous Anesthesia in Patients Undergoing Breast Cancer Surgery: a Randomized Controlled Trial [NCT05435911]66 participants (Actual)Interventional2022-08-02Completed
The Impact of Administration of Flumazenil on the Emergence Delirium in Patients Anesthetized With Remimazolam: a Prospective Randomized Single-blind Study [NCT05681377]Phase 468 participants (Actual)Interventional2023-03-05Completed
Rapid Benzodiazepine Detoxification Using Flumazenil [NCT00000246]Phase 210 participants (Actual)Interventional1993-01-31Completed
Department of Anesthesiology, Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Research Center for Neuro-Oncology Interaction , Institute of Basic Medicine and Cancer, Chinese Academy of Sciences [NCT05468671]Phase 434 participants (Actual)Interventional2021-01-04Completed
Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis. [NCT01651520]60 participants (Actual)Interventional2013-06-30Active, not recruiting
Open Label, Randomized, Three-way Crossover Study to Assess the Safety and the Pharmacokinetics of Sublingual Flumazenil (CRLS035) in Healthy Adults [NCT01655914]Phase 110 participants (Actual)Interventional2010-07-31Completed
Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam in Elderly Patients Undergoing Hip Joint Surgery: a Prospective Randomized Controlled Study. [NCT05939674]22 participants (Anticipated)Interventional2023-09-19Recruiting
PET With [18F]Flumazenil as an Index of Neurodegeneration in MS: Sensitivity at an Early Disease Stage and Pathophysiological Meaning [NCT03825601]45 participants (Anticipated)Interventional2019-02-01Not yet recruiting
A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention [NCT00262639]Phase 2/Phase 360 participants (Actual)Interventional2005-12-31Completed
Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson [NCT03440112]Phase 1/Phase 234 participants (Actual)Interventional2018-01-29Completed
A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors [NCT01183312]Phase 1/Phase 210 participants (Actual)Interventional2010-09-30Completed
GABA Antagonist to Improve Reversal of Anesthesia: a Double Blind Study With High-density EEG Surveillance [NCT04329585]60 participants (Anticipated)Interventional2020-03-25Recruiting
Reversal of Remimazolam by a Single Dose of Flumazenil After Monitored Anesthesia Care in Gynecological Ambulatory Surgery: a Prospective Randomized Controlled Trial [NCT05382806]224 participants (Actual)Interventional2022-08-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00262639 (2) [back to overview]Percent Days Abstinent
NCT00262639 (2) [back to overview]Percent Subjects Completely Abstinent
NCT01183312 (7) [back to overview]Change in Psychomotor Vigilance Task (PVT) Median Reaction Time
NCT01183312 (7) [back to overview]Change in Stanford Sleepiness Scale
NCT01183312 (7) [back to overview]PVT Additional Measure #1, Change in Lapse Frequency
NCT01183312 (7) [back to overview]PVT Additional Measure #2, Change in Duration of Lapse Domain
NCT01183312 (7) [back to overview]PVT Additional Measure #3, Change in Optimum Response Times
NCT01183312 (7) [back to overview]PVT Additional Measure #4, Change in False Response Frequency
NCT01183312 (7) [back to overview]PVT Additional Measure #5, Change in Visual Analog Scale Rating of Sleepiness at the Completion of PVT
NCT02899156 (7) [back to overview]Average Duration of Study Infusion
NCT02899156 (7) [back to overview]Average Maximum Rate of Study Infusion
NCT02899156 (7) [back to overview]Intensive Care Unit Length of Stay
NCT02899156 (7) [back to overview]Number of Delirium-free Days
NCT02899156 (7) [back to overview]Number of Mechanical Ventilator Free Days
NCT02899156 (7) [back to overview]Number of Participants With Delirium Resolution
NCT02899156 (7) [back to overview]Occurrence of Agitation Requiring Use of Rescue Sedatives While on Study Infusion
NCT03440112 (2) [back to overview]Change in Quantitative Biomechanics 1 (Clinical Motor Ratings MDS-UPDRS)
NCT03440112 (2) [back to overview]Change in Quantitative Biomechanics 2 (MiniBESTest Dynamic Balance Scale Sensory Subscore)
NCT03462641 (2) [back to overview]PIGD Score Change
NCT03462641 (2) [back to overview]Postural Instability and Gait Disorder (PIGD) Score

Percent Days Abstinent

percent days abstinent during treatment (NCT00262639)
Timeframe: Weeks 1 to 6

Interventionpercent days (Mean)
Low CIWA Flumazenil/Gabapentin70.8
Low CIWAar Placebo86.1
High CIWAar Placebo75.9
High CIWAar Flumazenil/Gabapentin95.9

[back to top]

Percent Subjects Completely Abstinent

percent of subjects completely abstinent during the six week medication study study (NCT00262639)
Timeframe: 6 week trial

Interventionpercent of participants (Number)
Low CIWA Flumazenil/Gabapentin44
Low CIWAar Placebo19
High CIWAar Placebo33
High CIWAar Flumazenil/Gabapentin71

[back to top]

Change in Psychomotor Vigilance Task (PVT) Median Reaction Time

The PVT measures the reaction time to button press following the presentation of a visual stimulus, reported here as the median reaction time for multiple presentations during the 10 minute task. The measure used was the change in median reaction time from baseline to drug administration, where the median reaction time at each of the time points (below) was averaged to provide a single on-treatment value for median reaction time. The measure was then calculated as baseline value - treatment value, such that higher numbers denote improvement from baseline. (NCT01183312)
Timeframe: 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject)

Interventionmsec (Mean)
Placebo-9.86
Sublingual Flumazenil-4.46

[back to top]

Change in Stanford Sleepiness Scale

The Stanford Sleepiness Scale (SSS) is a subjective rating of sleepiness, with score ranging from 1 to 7, where higher values reflect more severe sleepiness. The measure used was change in SSS from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). (NCT01183312)
Timeframe: 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject)

Interventionunits on a scale (Mean)
Placebo0.84
Sublingual Flumazenil0.26

[back to top]

PVT Additional Measure #1, Change in Lapse Frequency

A PVT lapse is defined as a reaction time exceeding 500 msec following the presentation of a single stimulus, which are then summed for the entire 10 minute PVT testing period. The measure used was the change in the frequency of lapses from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). (NCT01183312)
Timeframe: 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject)

Interventionnumber of lapses during PVT testing (Mean)
Placebo-3.3
Sublingual Flumazenil-2.6

[back to top]

PVT Additional Measure #2, Change in Duration of Lapse Domain

The PVT duration of lapse domain is defined as the reciprocal of the reaction time averaged across the slowest 10% of responses. The measure used was the change in duration of lapse domain from baseline to drug administration (calculated as baseline value - average value with study drug, where lower numbers denote improvement from baseline). (NCT01183312)
Timeframe: 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject)

Intervention1/msec (Mean)
Placebo0.18
Sublingual Flumazenil0.25

[back to top]

PVT Additional Measure #3, Change in Optimum Response Times

The optimum response times is defined as the reciprocal of the reaction time averaged across the fastest 10% of responses. The measure used was the change in optimum response time from baseline to following drug administration (calculated as baseline value - average value with study drug, where lower numbers denote improvement from baseline). (NCT01183312)
Timeframe: 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject)

Intervention1/msec (Mean)
Placebo-0.02
Sublingual Flumazenil-0.04

[back to top]

PVT Additional Measure #4, Change in False Response Frequency

The false response frequency is defined as the number of button presses when no stimulus is presented. The measure used was the change in false response frequency from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). (NCT01183312)
Timeframe: 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject)

Interventionnumber of false starts (Mean)
Placebo0.09
Sublingual Flumazenil-0.38

[back to top]

PVT Additional Measure #5, Change in Visual Analog Scale Rating of Sleepiness at the Completion of PVT

At the end of the 10 minute PVT testing period, subjects were asked to rate their current level of sleepiness along a line, which was transformed into a numeric value from 1-10, such that high levels indicated more severe subjective sleepiness. The measure used was the change in this rating from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). (NCT01183312)
Timeframe: 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject)

Interventionunits on a scale (Mean)
Placebo1.23
Sublingual Flumazenil1.01

[back to top]

Average Duration of Study Infusion

average duration of time patient was randomized to each infusion up to 72 hours (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

Interventionhours (Mean)
Flumazenil Group54.8
Placebo Group58.2

[back to top]

Average Maximum Rate of Study Infusion

average maximum rate (ml/hr) during the 72 hours after study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

Interventionmilliliters per hour (Mean)
Flumazenil Group5
Placebo Group5.2

[back to top]

Intensive Care Unit Length of Stay

length of time that the patient was admitted to an intensive care unit service during the hospital stay (NCT02899156)
Timeframe: duration of admission to the intensive care unit

Interventiondays (Mean)
Flumazenil Group7.8
Placebo Group7

[back to top]

Number of Delirium-free Days

Defined by the number of days in the 14-day period after randomization that the patient was alive and not delirious (i.e. CAM-ICU negative). Zero delirium-free days will be observed for patients that die within the 14-day period. (NCT02899156)
Timeframe: up to 14 days after randomization

Interventiondays (Median)
Flumazenil Group12.7
Placebo Group9.2

[back to top]

Number of Mechanical Ventilator Free Days

number of days within the first 28 days after enrollment that the patient was free from needing mechanical ventilation (NCT02899156)
Timeframe: up to 28 days after randomization

Interventiondays (Mean)
Flumazenil Group23.6
Placebo Group24.9

[back to top]

Number of Participants With Delirium Resolution

defined by the proportion of patients who were delirium free at 14 days after randomization (NCT02899156)
Timeframe: up to 14 days after randomization

InterventionParticipants (Count of Participants)
Flumazenil Group9
Placebo Group7

[back to top]

Occurrence of Agitation Requiring Use of Rescue Sedatives While on Study Infusion

number of times that a RASS score of + 2 to +4 occurred that did not resolve with decreasing study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion

InterventionParticipants (Count of Participants)
Flumazenil Group0
Placebo Group0

[back to top]

Change in Quantitative Biomechanics 1 (Clinical Motor Ratings MDS-UPDRS)

We will use the total Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III - motor scale rating scores to assess motor function. Scale from 0-132, higher scores indicate worse motor outcomes. Outcome measure was collected during dopaminergic medication ON state. (NCT03440112)
Timeframe: Day 1 (before treatment administration), day 7 (after 7 days of treatment), and day 14 (7 days of treatment discontinuation).

,,
Interventionunits on a scale (Median)
Day 1Day 7Day 14
Clarithromycin (Active or Placebo)2823.5022
Placebo Cream3431.5034
Transdermal Flumazenil (Active)3836.7532.75

[back to top]

Change in Quantitative Biomechanics 2 (MiniBESTest Dynamic Balance Scale Sensory Subscore)

MiniBEST sensory subscore measures an individual's ability to maintain balance under conditions of sensory constrain and unstable/inclined standing surface. It is is computed as a sum of MiniBEST items 7, 8, and 9.The score ranges from 0 to 6, with 0 indicating inability to balance under all of the condition, and 6 indicating no difficulty in maintaining balance under any of the conditions (lower score indicates worse balance). Outcome measure was collected during dopaminergic medication ON state. (NCT03440112)
Timeframe: Day 1 (before treatment administration), day 7 (after 7 days of treatment), and day 14 (7 days of treatment discontinuation).

,,
Interventionunits on a scale (Mean)
Day 1Day 7Day 14
Clarithromycin (Active or Placebo)65.676
Placebo Cream665.82
Transdermal Flumazenil (Active)5.545.826

[back to top]

PIGD Score Change

Difference in PIGD score from pre-infusion to post-infusion. Only observations where PIGD score change is less than 0 (decrease) are retained, as the hypothesis we are interested is whether the effect magnitude of flumazenil on PIGD score depends on baseline GABA-A receptor binding as assesed by FMZ PET. (NCT03462641)
Timeframe: up to 3 hours (including pre and post infusion motor evaluation)

InterventionChange in PIGD Score (Mean)
Placebo Responders-1.375
Flumazenil Responders-2.500

[back to top]

Postural Instability and Gait Disorder (PIGD) Score

"Postural Instability and Gait Disorder (PIGD) score is a subscale score of MDS-UPDRS scale.~It is computed as a sum of following MDS-UPDRS items:~3.10 Gait~3.11 Freezing of gait~3.12 Postural stability~3.13 Posture~Minimal possible score is 0, maximal possible score is 16. Higher scores indicate greater severity of PIGD symptoms (worse outcome)." (NCT03462641)
Timeframe: up to 3 hours (including pre and post infusion motor evaluation)

,
Interventionscore on a scale (Mean)
Before InfusionAfter Infusion
Flumazenil4.6254.09
Placebo4.6254.23

[back to top]